基于造血干细胞研究妊娠期核苷类逆转录酶抑制剂暴露抑制子代造血功能的机制
|
摘要
第一部分孕期不同HAART方案暴露对HIV感染母亲及HIV未感染新生儿的影响
目的:了解孕期接受高效抗逆转录病毒治疗（HAART）方案预防HIV母婴传播的安全性和有效性，探讨两种不同HAART方案对妊娠结局、孕妇和胎儿造血及免疫功能的影响。方法:71名单胎妊娠HIV感染孕妇按照HAART方案的不同分为含齐多夫定（AZT）组40人、不含AZT组31人，以40名健康孕妇为对照组。HIV阳性孕妇自妊娠14周及14周以后开始抗病毒治疗，含AZT组的HAART方案为齐多夫定+拉米夫定（AZT+3TC）联合克力芝（LPV/r）或依非那仑（EFV）或奈韦拉平（NVP），不含AZT组的HAART方案为替诺福韦（TDF）+3TC联合LPV/r或EFV或NVP。采集开始抗病毒治疗时和分娩前孕妇肘静脉血、脐带血，进行血细胞参数测定和CD4+、CD8+T淋巴细胞测定，同时收集孕妇和新生儿基本信息进行分析，婴儿出生后4～6周及4个月进行HIV-1-DNA核酸测定。结果:
1HAART治疗的两组孕妇当中，无妊娠期高血压疾病和妊娠期糖尿病的发生；HIV阳性母亲分娩新生儿无HIV感染发生，未观察到新生儿出生缺陷的发生，无死胎和死产发生。
2三组均无新生儿重度窒息发生，轻度窒息发生率无显著差异（P＞0.05）。两HAART暴露组之间新生儿脐带血T淋巴细胞相关指标均无显著性差异（P＞0.05）。两HAART组出生体重低于对照组（P＜0.05）。三组低出生体重发生率分别为15.00%、16.13%、5.00%，两治疗组高于对照组（P＜0.05）。
3含AZT组的中位治疗时间为20周，不含AZT组中位治疗时间为21周。两治疗组开始治疗时CD4+T淋巴细胞计数、CD4/CD8无差异；分娩前含AZT组孕妇CD4+T淋巴细胞计数560.32±226.10个/mm3，高于不含AZT组的483.38±246.50个/mm3，含AZT组CD4/CD8显著高于不含AZT组（P＜0.05）。分娩前含AZT组CD4+T淋巴细胞较开始治疗时均数上升了129.79个/mm3，升幅达30.15%，CD4/CD8升高，CD8+T淋巴细胞均数降低415.97个/mm3，降幅为29.57%，P＜0.05；而不含AZT组上述指标虽有改变但没有统计学意义。
4分娩前含AZT组与正常对照组相比，RBC、Hb、HCT、N显著降低，MCV、MCH、RDW显著增高（P＜0.05）；两HAART组相比，含AZT组RBC降低、L显著降低，MCV、MCH、RDW显著增高（P＜0.05）；各组间WBC和PLT没有统计学差异。三组孕妇轻度贫血的发生率没有统计学差异（P＞0.05），含AZT组孕妇中度贫血发生率高于其他两组（P＜0.05）。
5新生儿脐带血含AZT组较对照组RBC、Hb、HCT、N显著降低，MCV、MCH、RDW、L、PLT显著增高（P＜0.05）；两HAART组相比，含AZT组RBC、Hb、HCT显著降低，但MCV、RDW显著增高（P＜0.05）；各组间WBC没有统计学差异。HAART暴露的两组轻度贫血发生率较对照组高（P＜0.05）；含AZT组新生儿轻度、中度贫血较不含AZT组更多见（P＜0.05）。
结论：
1、长疗程HAART治疗后，HIV母婴传播率接近为零，孕期HAART治疗安全、有效；
2、孕期采用长疗程含AZT的HAART方案有助于孕妇的免疫重建；
3、孕期含AZT的HAART暴露导致孕妇及新生儿巨幼红细胞性贫血和中性粒细胞减少，新生儿血小板增多。
第二部分妊娠期齐多夫定干预对子代造血干/祖细胞抑制效应的研究
目的：系统观察和阐明齐多夫定对新生儿、新生鼠造血干/祖细胞活性抑制效应的变化规律。
方法：针对齐多夫定干预造血干/祖细胞活性的影响，进行三方面研究：
1在临床研究方面，HAART暴露的新生儿脐血分离单个核细胞，流式细胞术检测CD34+细胞比例，培养粒单系祖细胞(CFU-GM)、红系祖细胞(BFU-E)以及巨核系祖细胞(CFU-Meg)并计算克隆形成集落数；
2细胞学层次研究：取脐血造血干/祖细胞、新生小鼠骨髓单个核细胞，在CFU-GM、BFU-E和CFU-Meg体系和造血干/祖细胞悬浮培养体系中，进行体外AZT干预，浓度分别为0.1μM、0.5μM、1.0μM、2.0μM、4.0μM，观察与计算成集落数，流式细胞术检测干预后脐血造血干/祖细胞、小鼠骨髓单个核细胞的凋亡率；
3Balb/c孕小鼠宫内暴露，AZT剂量为5.0mg/日/只和10.0mg/日/只，干预时间为孕期第10天至分娩，检测新生鼠CFU-GM、BFU-E和CFU-Meg成集落数。
结果：临床15例HAART暴露脐血单个核细胞中，CD34+细胞阳性率为22.6±9.6%以及CFU-GM、 BFU-E和CFU-Meg成集落数显著低于正常脐血水平；在体外AZT干预体系中，新生鼠骨髓单个核细胞和脐血造血干/祖细胞，在0.5μM以上浓度，CFU-GM、BFU-E和CFU-Meg成集落数显著降低，且凋亡率明显升高，而在0.1μM浓度，凋亡率变化不明显，CFU-GM成集落数明显降低，但BFU-E和CFU-Meg成集落数只有降低趋势。在不同剂量AZT宫内暴露新生小鼠骨髓单个核细胞，CFU-GM、BFU-E和CFU-Meg成集落数明显低于正常对照新生小鼠。结论：妊娠期齐多夫定对造血干/祖细胞活性表现为明显的抑制效应，造血干/祖细胞凋亡，估计与齐多夫定线粒体毒性有关。
第三部分齐多夫定干预对子代造血干细胞自我更新信号通路调控的实验研究
目的：探索齐多夫定（AZT）对造血干细胞自我更新相关信号通路PI3K/Akt/mTOR和相关分子Bmi-1的变化规律，明确其对造血干细胞影响的分子机制。
方法：Balb/c孕小鼠AZT干预，AZT剂量分别为5.0mg/日/只和10.0mg/日/只，暴露时间为孕期第10天至分娩；取新生鼠骨髓细胞，Ficoll分离后，采用qRT-PCR与Western blot方法检测PI3K/Akt/mTOR和相关分子Bmi-1、PTEN的表达水平变化。对照组分别为正常新生鼠与成体小鼠和老年小鼠。
结果：宫内AZT暴露的新生小鼠的PI3K/Akt/mTOR信号通路中，mTOR水平表达有升高趋势，与成体小鼠无明显区别，但明显低于老年小鼠，而PTEN基因的表达无显著变化；Bmi-1基因表达水平有较正常对照新生鼠和成体小鼠高，但明显低于老年对照小鼠。AZT宫内暴露新生小鼠P70S6、4EBP1D较正常新生小鼠升高但低于老年小鼠（P <0.05），老年小鼠上述蛋白表达低于成年小鼠（P <0.05）。
结论：AZT对新生鼠造血干细胞自我更新相关信号通路关键分子mTOR与Bmi-1存在有限影响，仍可维持在较为正常调控水平范畴。
PART I
CLINICAL OBSERVATION OF DIFFERENT HAARTREGIMENS ON HIV-INFECTED PREGNANTWOMEN AND HIV-UNINFECTED NEWBORNS
Objective: To explore the effectiveness and safety of pregnant women andnewborns exposed to highly active antiretroviral therapy (HAART) duringpregnancy; to observe the pregnant results and changes of maternal or fetalhematopoiesis and immune function in two different regimen of HAART.
Methods: According to the different HAART regimens,71HIV-infectedpregnant women with single birth were divided into2groups,40ofcontaining zidovudine (AZT) group（AZT group）,31of AZT-free group,40healthy pregnant women in the control group. The antiretroviral therapy wasbegun in or after the14th pregnant week. The HAART regimens of the AZTgroup were AZT+3TC+LPV/r or+EFV or+NVP, the regimens of theAZT-free group were TDF+3TC+LPV/r or+EFV or+NVP. The samples of venous blood of the maternal and umbilical cord blood were collected indifferent points of time respectively, before antiretroviral treatment, beforedelivery and after delivery. The clinical research information as fellows:①the basic clinical information of the pregnant women and newborns;②hematologic parameters;③CD4+, CD8+T lymphocytes in peripheral blood;④the index of HIV nucleic acid was detected in4to6weeks and4monthsafter birth. Results:(1) Among two groups of the HAART, there were nogestational hypertension and gestational diabetes, and there were no birthdefects, stillbirth and MTCT in newborns.(2) No severe neonatal asphyxiaoccurred, and there were not statistically significant difference in mildasphyxia among the three groups (P>0.05). There were not significantdifferences between two therapy groups in umbilical cord blood levels of Tlymphocytes. The birth weights of newborns exposed to HAART were lowerthan the control group (P <0.05). The low birth weight rate were15.00%,16.13%and5.00%in the three groups, the rates of the two therapy groupswere higher than the control group (P <0.05).(3) The median duration oftreatment in AZT group was20weeks, while in the AZT-free group was21weeks; before the treatment, there were no significant differences between twotreatment groups in CD4+T lymphocyte count and CD4/CD8rate. But beforedelivery, CD4+T lymphocyte count and CD4/CD8in the AZT group weresignificantly higher than the AZT-free group (P <0.05), CD4+was560.32±226.10cells/mm3and CD4/CD8rate was0.63±0.29in AZT grouprespectively. Before delivery, the CD4+T lymphocyte of the AZT group wassignificantly higher than that before therapy, the mean increased and reachedto129.79cells/mm3, the increase was30.15%(P <0.05). While CD8+Tlymphocyte was significant lower than that before therapy， the mean decreased and reached to415.97cells/mm3，the decrease was29.57%(P <0.05). In addition, the rate of CD4/CD8increased significantly (P＜0.05). Inthe AZT-free group, there were no such significant changes of lymphocyteindexes in the two points of time.(4) Before delivery, the hematologicparameters of pregnant women with megaloblastic anemia in the AZT groupcompared with it of the control group, the statistical results as fellows: RBC,Hb, HCT and N decreased (P <0.05), MCV, MCH and RDW increased (P <0.05). Among the three groups, there were no significant differences in WBC,PLT and mild anemia (P>0.05); but in AZT group, the rate of moderateanemia reached to17.50%, it was more significant higher than other groups (P<0.05).(5) Among three groups, there were significant differences in RBC,Hb, HCT, MCV, MCH, RDW, N, L and PLT of umbilical cord blood ofnewborns (P <0.01), but there was no significant difference in WBC. In theAZT group, Megaloblastic anemia of newborns occurred easily; comparedwith the control group, the changes of hematologic parameters: RBC, Hb,HCT and N decreased (P <0.05), but MCV, MCH, RDW and L increased (P<0.05). In the two groups exposed to HAART, the rates of mild anemia were52.50%and29.03%and more significant higher than that of the control group(P <0.05). In the AZT group，the rate of moderate anemia was17.50%, andmore significant higher than that in the AZT-free group (P <0.05).Conclusion:①The MTCT rate of HIV was the lower-level because of a longterm HAART treatment, it show that there are enough effectiveness and safetyin HAART.②In the state of immune reconstruction, the long term AZ-containing HAART regimen is better than AZT-free regimen.③Duringpregnancy, maternal and neonatal megaloblastic anemia occur easily innewborns and pregnancy women with AZT-containing HAART exposure.
PART ⅡRESEARCH ON INHIBITIONS OF OFFSPRINGHEMATOPOIETIC STEM/PROGENITOR CELLACTIVITY CAUSED BY ZIDOVUDINE DURINGPREGNANCY
Objectives: To observe the suppressions of hematopoietic stem/progenitorcell activity of newborn and newborn mice caused by the exposure ofzidovudine(AZT). Methods: The research of zidovudine intervention onhematopoietic stem/progenitor cell activity:①The clinical research: thesamples of umbilical cord blood of newborns exposed to HAART werecollected；the indexes of hematopoietic stem/progenitor cell activity asfellows: the proportion of CD34+cells detected by flow cytometer (FCM) andthe colony-forming colonies of granulocytes monophyletic progenitor cells(CFU-GM), erythroid progenitor cells (BFU-E) and megakaryocyte progenitorcells (CFU-Meg).②AZT intervention in vitro: umbilical cord bloodhematopoietic stem/progenitor cells and bone marrow cells of newborn micewere isolated and cultured in vitro. The concentrations of AZT were0.1μM,0.5μM,1.0μM,2.0μM and4.0μM respectively. The indexes of hematopoieticstem/progenitor cell activity as fellows: the colony-forming colonies ofCFU-GM, BFU-E, CFU-Meg and apoptosis rates of hematopoietic stem/ progenitor cells detected by FCM.③The pregnancy Balb/c mice wereexposed to AZT with the dose of5.0mg/day and10.0mg/day, exposureperiods, from the10thday of pregnancy to birth. The colony-forming coloniesof CFU-GM, BFU-E, CFU-Meg were measured in monocytes of bone marrowcell of newborn mice. Results: In15cases of cord blood of newborn ofpregnancy women exposed to HAART, the positive rate of CD34+cells was22.6±9.6%and the CFU-GM, BFU-E and CFU-Meg were significantlylower than normal levels (P<0.05). Above the concentrations of0.5μM AZT,the number of colonies in the CFU-GM, BFU-E and CFU-Meg of bonemarrow cells of newborn mice and hematopoietic stem/progenitor cells ofumbilical cord blood were significantly reduced, while the rates of apoptosiswas significantly higher than control in vitro. In the concentration of0.1μMAZT, the rate of apoptosis was not significantly changed, the CFU-GMcolonies were significantly reduced, and the BFU-E and the CFU-Megcolonies decreased, but the differences were not significant. In different dosesof AZT, the CFU-GM, the BFU-E and the CFU-Meg colonies of newbornswere significant less than normal levels in vivo. Conclusions: In thenewborns of pregnancy mice exposed to AZT, the activity and apoptosis ofhematopoietic stem/progenitor cells are inhibited and increased respectively.It suggests that mitochondrial toxicity of hematopoietic stem/progenitor cellscaused by AZT.
PART ⅢRESEARCH ON SELF-RENEWAL SIGNALINGPATHWAY OF OFFSPRING HEMATOPOIETIC STEMCELL REGULATED BY ZIDOVUDINE
Objectives: To investigate the regulation of self-renewal signaling pathwayPI3K-AKT-mTOR and Bmi-1gen of hematopoietic stem/progenitor cells, innewborns of pregnancy mice exposed to Zidovudine (AZT). Methods: Thepregnancy Balb/c mice were exposed to AZT with the dose of5.0mg/day and10.0mg/day, exposure periods, from the10thday of pregnancy to birth. Theoffspring hematopoietic stem/progenitor cells of bone marrows of wereisolated by Ficoll. The self-renewal signaling pathways PI3K/Akt/mTOR,Bmi-1and PTEN gene expression were measured by qRT-PCR and Westernblot. In addition, the control group was normal newborn mice, adult mice andaged mice. Results: In newborn mice of pregnancy Balb/c mice exposed toAZT, the mTOR expression levels of offspring hematopoietic stem/progenitor cells increased, but had no significant differences with adult mice,and were significantly less than the aged mice; while PTEN gene expressionwere not significant changes; Bmi-1gene expression level were more higherthan the normal newborn mice and adult mice, but were significantly less thanthe aged mice. The changes of protein expressions of P70S6,4EBP1D ofoffspring hematopoietic stem/progenitor cells as follows: newborn mice
目的:了解孕期接受高效抗逆转录病毒治疗（HAART）方案预防HIV母婴传播的安全性和有效性，探讨两种不同HAART方案对妊娠结局、孕妇和胎儿造血及免疫功能的影响。方法:71名单胎妊娠HIV感染孕妇按照HAART方案的不同分为含齐多夫定（AZT）组40人、不含AZT组31人，以40名健康孕妇为对照组。HIV阳性孕妇自妊娠14周及14周以后开始抗病毒治疗，含AZT组的HAART方案为齐多夫定+拉米夫定（AZT+3TC）联合克力芝（LPV/r）或依非那仑（EFV）或奈韦拉平（NVP），不含AZT组的HAART方案为替诺福韦（TDF）+3TC联合LPV/r或EFV或NVP。采集开始抗病毒治疗时和分娩前孕妇肘静脉血、脐带血，进行血细胞参数测定和CD4+、CD8+T淋巴细胞测定，同时收集孕妇和新生儿基本信息进行分析，婴儿出生后4～6周及4个月进行HIV-1-DNA核酸测定。结果:
1HAART治疗的两组孕妇当中，无妊娠期高血压疾病和妊娠期糖尿病的发生；HIV阳性母亲分娩新生儿无HIV感染发生，未观察到新生儿出生缺陷的发生，无死胎和死产发生。
2三组均无新生儿重度窒息发生，轻度窒息发生率无显著差异（P＞0.05）。两HAART暴露组之间新生儿脐带血T淋巴细胞相关指标均无显著性差异（P＞0.05）。两HAART组出生体重低于对照组（P＜0.05）。三组低出生体重发生率分别为15.00%、16.13%、5.00%，两治疗组高于对照组（P＜0.05）。
3含AZT组的中位治疗时间为20周，不含AZT组中位治疗时间为21周。两治疗组开始治疗时CD4+T淋巴细胞计数、CD4/CD8无差异；分娩前含AZT组孕妇CD4+T淋巴细胞计数560.32±226.10个/mm3，高于不含AZT组的483.38±246.50个/mm3，含AZT组CD4/CD8显著高于不含AZT组（P＜0.05）。分娩前含AZT组CD4+T淋巴细胞较开始治疗时均数上升了129.79个/mm3，升幅达30.15%，CD4/CD8升高，CD8+T淋巴细胞均数降低415.97个/mm3，降幅为29.57%，P＜0.05；而不含AZT组上述指标虽有改变但没有统计学意义。
4分娩前含AZT组与正常对照组相比，RBC、Hb、HCT、N显著降低，MCV、MCH、RDW显著增高（P＜0.05）；两HAART组相比，含AZT组RBC降低、L显著降低，MCV、MCH、RDW显著增高（P＜0.05）；各组间WBC和PLT没有统计学差异。三组孕妇轻度贫血的发生率没有统计学差异（P＞0.05），含AZT组孕妇中度贫血发生率高于其他两组（P＜0.05）。
5新生儿脐带血含AZT组较对照组RBC、Hb、HCT、N显著降低，MCV、MCH、RDW、L、PLT显著增高（P＜0.05）；两HAART组相比，含AZT组RBC、Hb、HCT显著降低，但MCV、RDW显著增高（P＜0.05）；各组间WBC没有统计学差异。HAART暴露的两组轻度贫血发生率较对照组高（P＜0.05）；含AZT组新生儿轻度、中度贫血较不含AZT组更多见（P＜0.05）。
结论：
1、长疗程HAART治疗后，HIV母婴传播率接近为零，孕期HAART治疗安全、有效；
2、孕期采用长疗程含AZT的HAART方案有助于孕妇的免疫重建；
3、孕期含AZT的HAART暴露导致孕妇及新生儿巨幼红细胞性贫血和中性粒细胞减少，新生儿血小板增多。
第二部分妊娠期齐多夫定干预对子代造血干/祖细胞抑制效应的研究
目的：系统观察和阐明齐多夫定对新生儿、新生鼠造血干/祖细胞活性抑制效应的变化规律。
方法：针对齐多夫定干预造血干/祖细胞活性的影响，进行三方面研究：
1在临床研究方面，HAART暴露的新生儿脐血分离单个核细胞，流式细胞术检测CD34+细胞比例，培养粒单系祖细胞(CFU-GM)、红系祖细胞(BFU-E)以及巨核系祖细胞(CFU-Meg)并计算克隆形成集落数；
2细胞学层次研究：取脐血造血干/祖细胞、新生小鼠骨髓单个核细胞，在CFU-GM、BFU-E和CFU-Meg体系和造血干/祖细胞悬浮培养体系中，进行体外AZT干预，浓度分别为0.1μM、0.5μM、1.0μM、2.0μM、4.0μM，观察与计算成集落数，流式细胞术检测干预后脐血造血干/祖细胞、小鼠骨髓单个核细胞的凋亡率；
3Balb/c孕小鼠宫内暴露，AZT剂量为5.0mg/日/只和10.0mg/日/只，干预时间为孕期第10天至分娩，检测新生鼠CFU-GM、BFU-E和CFU-Meg成集落数。
结果：临床15例HAART暴露脐血单个核细胞中，CD34+细胞阳性率为22.6±9.6%以及CFU-GM、 BFU-E和CFU-Meg成集落数显著低于正常脐血水平；在体外AZT干预体系中，新生鼠骨髓单个核细胞和脐血造血干/祖细胞，在0.5μM以上浓度，CFU-GM、BFU-E和CFU-Meg成集落数显著降低，且凋亡率明显升高，而在0.1μM浓度，凋亡率变化不明显，CFU-GM成集落数明显降低，但BFU-E和CFU-Meg成集落数只有降低趋势。在不同剂量AZT宫内暴露新生小鼠骨髓单个核细胞，CFU-GM、BFU-E和CFU-Meg成集落数明显低于正常对照新生小鼠。结论：妊娠期齐多夫定对造血干/祖细胞活性表现为明显的抑制效应，造血干/祖细胞凋亡，估计与齐多夫定线粒体毒性有关。
第三部分齐多夫定干预对子代造血干细胞自我更新信号通路调控的实验研究
目的：探索齐多夫定（AZT）对造血干细胞自我更新相关信号通路PI3K/Akt/mTOR和相关分子Bmi-1的变化规律，明确其对造血干细胞影响的分子机制。
方法：Balb/c孕小鼠AZT干预，AZT剂量分别为5.0mg/日/只和10.0mg/日/只，暴露时间为孕期第10天至分娩；取新生鼠骨髓细胞，Ficoll分离后，采用qRT-PCR与Western blot方法检测PI3K/Akt/mTOR和相关分子Bmi-1、PTEN的表达水平变化。对照组分别为正常新生鼠与成体小鼠和老年小鼠。
结果：宫内AZT暴露的新生小鼠的PI3K/Akt/mTOR信号通路中，mTOR水平表达有升高趋势，与成体小鼠无明显区别，但明显低于老年小鼠，而PTEN基因的表达无显著变化；Bmi-1基因表达水平有较正常对照新生鼠和成体小鼠高，但明显低于老年对照小鼠。AZT宫内暴露新生小鼠P70S6、4EBP1D较正常新生小鼠升高但低于老年小鼠（P <0.05），老年小鼠上述蛋白表达低于成年小鼠（P <0.05）。
结论：AZT对新生鼠造血干细胞自我更新相关信号通路关键分子mTOR与Bmi-1存在有限影响，仍可维持在较为正常调控水平范畴。
PART I
CLINICAL OBSERVATION OF DIFFERENT HAARTREGIMENS ON HIV-INFECTED PREGNANTWOMEN AND HIV-UNINFECTED NEWBORNS
Objective: To explore the effectiveness and safety of pregnant women andnewborns exposed to highly active antiretroviral therapy (HAART) duringpregnancy; to observe the pregnant results and changes of maternal or fetalhematopoiesis and immune function in two different regimen of HAART.
Methods: According to the different HAART regimens,71HIV-infectedpregnant women with single birth were divided into2groups,40ofcontaining zidovudine (AZT) group（AZT group）,31of AZT-free group,40healthy pregnant women in the control group. The antiretroviral therapy wasbegun in or after the14th pregnant week. The HAART regimens of the AZTgroup were AZT+3TC+LPV/r or+EFV or+NVP, the regimens of theAZT-free group were TDF+3TC+LPV/r or+EFV or+NVP. The samples of venous blood of the maternal and umbilical cord blood were collected indifferent points of time respectively, before antiretroviral treatment, beforedelivery and after delivery. The clinical research information as fellows:①the basic clinical information of the pregnant women and newborns;②hematologic parameters;③CD4+, CD8+T lymphocytes in peripheral blood;④the index of HIV nucleic acid was detected in4to6weeks and4monthsafter birth. Results:(1) Among two groups of the HAART, there were nogestational hypertension and gestational diabetes, and there were no birthdefects, stillbirth and MTCT in newborns.(2) No severe neonatal asphyxiaoccurred, and there were not statistically significant difference in mildasphyxia among the three groups (P>0.05). There were not significantdifferences between two therapy groups in umbilical cord blood levels of Tlymphocytes. The birth weights of newborns exposed to HAART were lowerthan the control group (P <0.05). The low birth weight rate were15.00%,16.13%and5.00%in the three groups, the rates of the two therapy groupswere higher than the control group (P <0.05).(3) The median duration oftreatment in AZT group was20weeks, while in the AZT-free group was21weeks; before the treatment, there were no significant differences between twotreatment groups in CD4+T lymphocyte count and CD4/CD8rate. But beforedelivery, CD4+T lymphocyte count and CD4/CD8in the AZT group weresignificantly higher than the AZT-free group (P <0.05), CD4+was560.32±226.10cells/mm3and CD4/CD8rate was0.63±0.29in AZT grouprespectively. Before delivery, the CD4+T lymphocyte of the AZT group wassignificantly higher than that before therapy, the mean increased and reachedto129.79cells/mm3, the increase was30.15%(P <0.05). While CD8+Tlymphocyte was significant lower than that before therapy， the mean decreased and reached to415.97cells/mm3，the decrease was29.57%(P <0.05). In addition, the rate of CD4/CD8increased significantly (P＜0.05). Inthe AZT-free group, there were no such significant changes of lymphocyteindexes in the two points of time.(4) Before delivery, the hematologicparameters of pregnant women with megaloblastic anemia in the AZT groupcompared with it of the control group, the statistical results as fellows: RBC,Hb, HCT and N decreased (P <0.05), MCV, MCH and RDW increased (P <0.05). Among the three groups, there were no significant differences in WBC,PLT and mild anemia (P>0.05); but in AZT group, the rate of moderateanemia reached to17.50%, it was more significant higher than other groups (P<0.05).(5) Among three groups, there were significant differences in RBC,Hb, HCT, MCV, MCH, RDW, N, L and PLT of umbilical cord blood ofnewborns (P <0.01), but there was no significant difference in WBC. In theAZT group, Megaloblastic anemia of newborns occurred easily; comparedwith the control group, the changes of hematologic parameters: RBC, Hb,HCT and N decreased (P <0.05), but MCV, MCH, RDW and L increased (P<0.05). In the two groups exposed to HAART, the rates of mild anemia were52.50%and29.03%and more significant higher than that of the control group(P <0.05). In the AZT group，the rate of moderate anemia was17.50%, andmore significant higher than that in the AZT-free group (P <0.05).Conclusion:①The MTCT rate of HIV was the lower-level because of a longterm HAART treatment, it show that there are enough effectiveness and safetyin HAART.②In the state of immune reconstruction, the long term AZ-containing HAART regimen is better than AZT-free regimen.③Duringpregnancy, maternal and neonatal megaloblastic anemia occur easily innewborns and pregnancy women with AZT-containing HAART exposure.
PART ⅡRESEARCH ON INHIBITIONS OF OFFSPRINGHEMATOPOIETIC STEM/PROGENITOR CELLACTIVITY CAUSED BY ZIDOVUDINE DURINGPREGNANCY
Objectives: To observe the suppressions of hematopoietic stem/progenitorcell activity of newborn and newborn mice caused by the exposure ofzidovudine(AZT). Methods: The research of zidovudine intervention onhematopoietic stem/progenitor cell activity:①The clinical research: thesamples of umbilical cord blood of newborns exposed to HAART werecollected；the indexes of hematopoietic stem/progenitor cell activity asfellows: the proportion of CD34+cells detected by flow cytometer (FCM) andthe colony-forming colonies of granulocytes monophyletic progenitor cells(CFU-GM), erythroid progenitor cells (BFU-E) and megakaryocyte progenitorcells (CFU-Meg).②AZT intervention in vitro: umbilical cord bloodhematopoietic stem/progenitor cells and bone marrow cells of newborn micewere isolated and cultured in vitro. The concentrations of AZT were0.1μM,0.5μM,1.0μM,2.0μM and4.0μM respectively. The indexes of hematopoieticstem/progenitor cell activity as fellows: the colony-forming colonies ofCFU-GM, BFU-E, CFU-Meg and apoptosis rates of hematopoietic stem/ progenitor cells detected by FCM.③The pregnancy Balb/c mice wereexposed to AZT with the dose of5.0mg/day and10.0mg/day, exposureperiods, from the10thday of pregnancy to birth. The colony-forming coloniesof CFU-GM, BFU-E, CFU-Meg were measured in monocytes of bone marrowcell of newborn mice. Results: In15cases of cord blood of newborn ofpregnancy women exposed to HAART, the positive rate of CD34+cells was22.6±9.6%and the CFU-GM, BFU-E and CFU-Meg were significantlylower than normal levels (P<0.05). Above the concentrations of0.5μM AZT,the number of colonies in the CFU-GM, BFU-E and CFU-Meg of bonemarrow cells of newborn mice and hematopoietic stem/progenitor cells ofumbilical cord blood were significantly reduced, while the rates of apoptosiswas significantly higher than control in vitro. In the concentration of0.1μMAZT, the rate of apoptosis was not significantly changed, the CFU-GMcolonies were significantly reduced, and the BFU-E and the CFU-Megcolonies decreased, but the differences were not significant. In different dosesof AZT, the CFU-GM, the BFU-E and the CFU-Meg colonies of newbornswere significant less than normal levels in vivo. Conclusions: In thenewborns of pregnancy mice exposed to AZT, the activity and apoptosis ofhematopoietic stem/progenitor cells are inhibited and increased respectively.It suggests that mitochondrial toxicity of hematopoietic stem/progenitor cellscaused by AZT.
PART ⅢRESEARCH ON SELF-RENEWAL SIGNALINGPATHWAY OF OFFSPRING HEMATOPOIETIC STEMCELL REGULATED BY ZIDOVUDINE
Objectives: To investigate the regulation of self-renewal signaling pathwayPI3K-AKT-mTOR and Bmi-1gen of hematopoietic stem/progenitor cells, innewborns of pregnancy mice exposed to Zidovudine (AZT). Methods: Thepregnancy Balb/c mice were exposed to AZT with the dose of5.0mg/day and10.0mg/day, exposure periods, from the10thday of pregnancy to birth. Theoffspring hematopoietic stem/progenitor cells of bone marrows of wereisolated by Ficoll. The self-renewal signaling pathways PI3K/Akt/mTOR,Bmi-1and PTEN gene expression were measured by qRT-PCR and Westernblot. In addition, the control group was normal newborn mice, adult mice andaged mice. Results: In newborn mice of pregnancy Balb/c mice exposed toAZT, the mTOR expression levels of offspring hematopoietic stem/progenitor cells increased, but had no significant differences with adult mice,and were significantly less than the aged mice; while PTEN gene expressionwere not significant changes; Bmi-1gene expression level were more higherthan the normal newborn mice and adult mice, but were significantly less thanthe aged mice. The changes of protein expressions of P70S6,4EBP1D ofoffspring hematopoietic stem/progenitor cells as follows: newborn mice
引文
[1] WHO. Core epidemiological slides HIV/AIDS estimates.2014;Available from: http://www.who.int/entity/hiv/data/2013_epi_core.ppt.
[2]中国疾病预防控制中心性病艾滋病预防控制中心.2013年11月全国艾滋病性病疫情及主要防治工作进展[J].中国艾滋病性病.2014(01):1.
[3]中华人民共和国国家卫生和计划生育委员会.我国艾滋病防控工作背景2013[cited201311-30]; Available from: http://www.nhfpc.gov.cn/jkj/s3586/201312/2b871ccd2ef446eb9542875d3d68bbca.shtml.
[4]王临虹,方利文,王前, et al.我国艾滋病母婴传播水平传播时期及干预效果研究[J].中国艾滋病性病.2008(05):435-8.
[5]王爱霞,王福祥,毛青, et al.艾滋病诊疗指南.中华医学会第五次全国艾滋病、病毒性丙型肝炎暨全国热带病学术会议.2011:22
[6]王临虹.艾滋病病毒感染孕产妇治疗及预防艾滋病母婴传播抗病毒药物使用手册[M].北京:人民卫生出版社;2007.1-2.
[7] Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartumantiretroviral regimens to prevent intrapartum HIV infection[J]. TheNew England journal of medicine.2012,366(25):2368-79.
[8] Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load,zidovudine treatment, and the risk of transmission of humanimmunodeficiency virus type1from mother to infant. Pediatric AIDSClinical Trials Group Protocol076Study Group[J]. The New Englandjournal of medicine.1996,335(22):1621-9.
[9] Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviralstrategies for the treatment of pregnant HIV-1-infected women andprevention of perinatal HIV-1transmission[J]. J Acquir Immune DeficSyndr.2002,29(5):484-94.
[10]中国疾病预防控制中心性病艾滋病预防控制中心.卫生计生委:1至9月新发现艾滋病病毒感染者约7万例2013[cited201312-01]; Available from: http://www.chinaids.org.cn/jkjy/sjazbr1/rdgz1/201312/t20131201_90833.htm.
[11]莫云,黄越华,李映.2007～2011年广西艾滋病及艾滋病病毒感染孕产妇死亡状况调查分析[J].中国临床新医学.2012(10):909-12.
[12]蒙春莲. HIV感染孕产妇HAART治疗对母婴传播的影响[J].广西医学.2011(11):1432-4.
[13]庞俊,黄绍标. HAART阻断HIV母婴传播效果观察[J].广西医学.2009(09):1254-5.
[14]刘冬梅,庞俊,韦淑珍, et al.不同孕期HIV/AIDS孕妇接受抗病毒治疗的效果评估[J].中华全科医学.2013(07):1061-2.
[15] Schramm DB, Meddows-Taylor S, Gray GE, et al. Low maternal viralloads and reduced granulocyte-macrophage colony-stimulating factorlevels characterize exposed, uninfected infants who develop protectivehuman immunodeficiency virus type1-specific responses[J]. Clinicaland vaccine immunology: CVI.2007,14(4):348-54.
[16] Mehta S, Hunter DJ, Mugusi FM, et al. Perinatal outcomes, includingmother-to-child transmission of HIV, and child mortality and theirassociation with maternal vitamin D status in Tanzania[J]. The Journalof infectious diseases.2009,200(7):1022-30.
[17] Cote HC, Raboud J, Bitnun A, et al. Perinatal exposure to antiretroviraltherapy is associated with increased blood mitochondrial DNA levelsand decreased mitochondrial gene expression in infants[J]. The Journalof infectious diseases.2008,198(6):851-9.
[1] UNAIDS. UNAIDS report on the global AIDS epidemic2013.2013; Available from: http://10.128.9.132/files/60780000000D7968/www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_
en.pdf.[2]中国疾病预防控制中心性病艾滋病预防控制中心.卫生计生委:1至9月新发现艾滋病病毒感染者约7万例2013[cited201312-01]; Available from: http://www.chinaids.org.cn/jkjy/sj
azbr1/rdgz1/201312/t20131201_90833.htm.[3]中华人民共和国国家卫生和计划生育委员会.我国艾滋病防控工作背景2013[cited201311-30]; Available from:http://www.nhfpc.gov.cn/jkj/s3586/201312/2b871ccd2ef446eb95
42875d3d68bbca.shtml.[4]王爱霞,王福祥,毛青, et al.艾滋病诊疗指南.中华医学会第五次全国艾滋病、病毒性丙型肝炎暨全国热带病学术会议.
2011:22[5] Important change in Sustiva (efavirenz) package insert: change from category C to D,March2005. Bristol-Myers Squibb Company [Internet].2006(Oct24). Available from: http://www.f-da.gov/medwatch/SAFETY/2005/Sustiva_DHCPletter-061005.pdf.
[6] Antiretroviral pregnancy registry international interim report for1January1989-31January2010. Antiretroviral PregnancyRegistry Steering Committee [Internet].2009. Available from:www.APRegistry.com.
[7] Recommendations for Use of Antiretroviral Drugs in PregnantHIV-1-Infected Women for Maternal Health and Interventions toReduce Perinatal HIV Transmission in the United States.Developed by the HHS Panel on Treatment of HIV-InfectedPregnant Women and Prevention of Perinatal Transmission-AWorking Group of the Office of AIDS Research AdvisoryCouncil (OARAC)[Internet].2011. Available from:http://aidsinfo.nih.gov/guidelines.
[8] Baroncelli S, Tamburrini E, Ravizza M, et al. Antiretroviraltreatment in pregnancy: a six-year perspective on recent trends inprescription patterns, viral load suppression, and pregnancyoutcomes[J]. AIDS patient care and STDs.2009,23(7):513-20.
[9] Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatmentof adult HIV infection:2010recommendations of theInternational AIDS Society-USA panel[J]. JAMA: the journal ofthe American Medical Association.2010,304(3):321-33.
[10] El Beitune P, Duarte G. Antiretroviral agents during pregnancy:consequences on hematologic parameters in HIV-exposed,uninfected newborn infant[J]. European journal of obstetrics,gynecology, and reproductive biology.2006,128(1-2):59-63.
[11] Feiterna-Sperling C, Weizsaecker K, Buhrer C, et al.Hematologic effects of maternal antiretroviral therapy andtransmission prophylaxis in HIV-1-exposed uninfected newborninfants[J]. J Acquir Immune Defic Syndr.2007,45(1):43-51.
[12] Baroncelli S, Pinnetti C, Genovese O, et al. Hematologicaleffects of zidovudine prophylaxis in newborn infants with andwithout prenatal exposure to zidovudine[J]. Journal of medicalvirology.2011,83(3):551-6.
[13] Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note ofcaution[J]. The Journal of infectious diseases.2012,206(11):1639-41.
[14] Ndirangu J, Newell ML, Bland RM, et al. Maternal HIVinfection associated with small-for-gestational age infants but notpreterm births: evidence from rural South Africa[J]. Hum Reprod.2012,27(6):1846-56.
[15]李爱杰,汪永忠. HIV感染妇女分娩婴儿低出生体质量情况及影响因素分析[J].中国皮肤性病学杂志.2013(02):161-2.
[16]金汉珍，黄德珉，官希吉.实用新生儿学[M].北京:人民卫生出版社.631.
[17]谢幸,苟文丽.妇产科学[M].北京:人民卫生出版社;2013.92.
[18]王前.抗逆转录病毒药物预防艾滋病母婴传播效果评价[博士]:中国疾病预防控制中心;2011:53.
[19]庞俊,黄绍标. HAART阻断HIV母婴传播效果观察[J].广西医学.2009(09):1254-5.
[20]蒙春莲. HIV感染孕产妇HAART治疗对母婴传播的影响[J].广西医学.2011(11):1432-4.
[21]李太生.艾滋病的免疫功能重建研究进展[J].传染病信息.2003(04):150-2.
[22] Smiatacz T.[Immune mechanisms in HIV infection and their rolein antiretroviral therapy][J]. Przeglad epidemiologiczny.2003,57(2):309-16.
[23] de Vincenzi I. Triple antiretroviral compared with zidovudine andsingle-dose nevirapine prophylaxis during pregnancy andbreastfeeding for prevention of mother-to-child transmission ofHIV-1(Kesho Bora study): a randomised controlled trial[J]. TheLancet infectious diseases.2011,11(3):171-80.
[24]张璐,王临虹,方利文.分娩方式与艾滋病母婴传播[J].中国艾滋病性病.2012(04):265-8.
[25] ACOG committee opinion scheduled Cesarean delivery and theprevention of vertical transmission of HIV infection. Number234,May2000(replaces number219, August1999)[J]. Internationaljournal of gynaecology and obstetrics: the official organ of theInternational Federation of Gynaecology and Obstetrics.2001,73(3):279-81.
[26] Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome inwomen infected with HIV-1receiving combination antiretroviraltherapy before versus after conception[J]. Sexually transmittedinfections.2009,85(2):82-7.
[27] Townsend CL, Cortina-Borja M, Peckham CS, et al.Antiretroviral therapy and premature delivery in diagnosedHIV-infected women in the United Kingdom and Ireland[J].AIDS.2007,21(8):1019-26.
[28] Kourtis AP, Schmid CH, Jamieson DJ, et al. Use of antiretroviraltherapy in pregnant HIV-infected women and the risk ofpremature delivery: a meta-analysis[J]. AIDS.2007,21(5):607-15.
[29] Briand N, Mandelbrot L, Le Chenadec J, et al. No relationbetween in-utero exposure to HAART and intrauterine growthretardation[J]. AIDS.2009,23(10):1235-43.
[30] Darak S, Darak T, Kulkarni S, et al. Effect of highly activeantiretroviral treatment (HAART) during pregnancy onpregnancy outcomes: experiences from a PMTCT program inwestern India[J]. AIDS patient care and STDs.2013,27(3):163-70.
[31] Parekh N, Ribaudo H, Souda S, et al. Risk factors for verypreterm delivery and delivery of very-small-for-gestational-ageinfants among HIV-exposed and HIV-unexposed infants inBotswana[J]. International journal of gynaecology and obstetrics:the official organ of the International Federation of Gynaecologyand Obstetrics.2011,115(1):20-5.
[32] Connor EM, Sperling RS, Gelber R. Reduction of maternal infanttransmission of human immunodeficiency virus type1withzidovudine treatment.Pediatric AIDS Clinical Trials GroupProtocol076Study Group[J]. N Engl Med.1994,331(18):1173-80.
[33] Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load,zidovudine treatment, and the risk of transmission of humanimmunodeficiency virus type1from mother to infant. PediatricAIDS Clinical Trials Group Protocol076Study Group[J]. TheNew England journal of medicine.1996,335(22):1621-9.
[34] Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al.Perinatal antiretroviral treatment and hematopoiesis inHIV-uninfected infants[J]. AIDS.2003,17(14):2053-61.
[35] Majluf-Cruz A, Luna-Castanos G, Trevino-Perez S, et al.Lamivudine-induced pure red cell aplasia[J]. American journal ofhematology.2000,65(3):189-91.
[36] Pluda JM, Cooley TP, Montaner JS, et al. A phase I/II study of2'-deoxy-3'-thiacytidine (lamivudine) in patients with advancedhuman immunodeficiency virus infection[J]. The Journal ofinfectious diseases.1995,171(6):1438-47.
[37] Marzolini C, Rudin C, Decosterd LA, et al. Transplacentalpassage of protease inhibitors at delivery[J]. AIDS.2002,16(6):889-93.
[38] Olagunju A, Owen A, Cressey TR. Potential effect ofpharmacogenetics on maternal, fetal and infant antiretroviral drugexposure during pregnancy and breastfeeding[J].Pharmacogenomics.2012,13(13):1501-22.
[39] Chappuy H, Treluyer JM, Jullien V, et al. Maternal-fetal transferand amniotic fluid accumulation of nucleoside analogue reversetranscriptase inhibitors in human immunodeficiencyvirus-infected pregnant women[J]. Antimicrobial agents andchemotherapy.2004,48(11):4332-6.
[40] Mirochnick M. Antiretroviral pharmacology in pregnant womenand their newborns[J]. Annals of the New York Academy ofSciences.2000,918:287-97.
[41] Kirmse B, Hobbs CV, Peter I, et al. Abnormal newborn screensand acylcarnitines in HIV-exposed and ARV-exposed infants[J].The Pediatric infectious disease journal.2013,32(2):146-50.
[42] Shah MM, Li Y, Christensen RD. Effects of perinatal zidovudineon hematopoiesis: a comparison of effects on progenitors fromhuman fetuses versus mothers[J]. AIDS.1996,10(11):1239-47.
[43] Huang SS, Barbour JD, Deeks SG, et al. Reversal of humanimmunodeficiency virus type1-associated hematosuppression byeffective antiretroviral therapy[J]. Clinical infectious diseases:an official publication of the Infectious Diseases Society ofAmerica.2000,30(3):504-10.
[44] Moore RD, Forney D. Anemia in HIV-infected patients receivinghighly active antiretroviral therapy[J]. J Acquir Immune DeficSyndr.2002,29(1):54-7.
[45] Berhane K, Karim R, Cohen MH, et al. Impact of highly activeantiretroviral therapy on anemia and relationship between anemiaand survival in a large cohort of HIV-infected women: Women'sInteragency HIV Study[J]. J Acquir Immune Defic Syndr.2004,37(2):1245-52.
[46]张时民.血常规中红细胞参数的诊断价值和意义[J].中国临床医生.2001(11):25-7.
[47] Lin CK, Lin JS, Chen SY, et al. Comparison of hemoglobin andred blood cell distribution width in the differential diagnosis ofmicrocytic anemia[J]. Archives of pathology&laboratorymedicine.1992,116(10):1030-2.
[48] Bessman JD, Gilmer PR, Jr., Gardner FH. Improvedclassification of anemias by MCV and RDW[J]. Americanjournal of clinical pathology.1983,80(3):322-6.
[49] Pinnetti C, Baroncelli S, Molinari A, et al. Common occurrenceof anaemia at the end of pregnancy following exposure tozidovudine-free regimens[J]. The Journal of infection.2011,63(2):144-50.
[50] European Collaborative Study. Exposure to antiretroviral therapyin utero or early life: the health of uninfected children born toHIV-infected women[J]. Acquir Immune Defic Syndr.2003,32(4):380-7.
[51] European Collaborative Study. Levels and patterns of neutrophilcell counts over the first8years of life in children of HIV-1infected mothers[J]. AIDS,18(15):2009-2017.2004,18(15):2009-17.
[52] Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increasedrisk of severe infant anemia after exposure to maternal HAART,Botswana[J]. J Acquir Immune Defic Syndr.2011,56(5):428-36.
[53] Steele RH, Keogh GL, Quin J, et al. Mean cell volume (MCV)changes in HIV-positive patients taking nucleoside reversetranscriptase inhibitors (NRTIs): a surrogate marker foradherence[J]. International journal of STD&AIDS.2002,13(11):748-54.
[54]王鸿利,顾荣泉,宁嗣宗.血液学及血液学检验[M].北京:人民卫生出版社;1997.
[55] Weiss G, Goodnough LT. Anemia of chronic disease[J]. The NewEngland journal of medicine.2005,352(10):1011-23.
[56] Friedman JS, Lopez MF, Fleming MD, et al. SOD2-deficiencyanemia: protein oxidation and altered protein expression revealtargets of damage, stress response, and antioxidantresponsiveness[J]. Blood.2004,104(8):2565-73.
[57] Evans TC, Jehle D. The red blood cell distribution width[J]. TheJournal of emergency medicine.1991,9Suppl1:71-4.
[58] Ferrucci L, Guralnik JM, Woodman RC, et al. Proinflammatorystate and circulating erythropoietin in persons with and withoutanemia[J]. The American journal of medicine.2005,118(11):1288.
[59] Taha TE KN, Gibbons A, et al. Effect of HIV-1antiretroviralprophylaxis on hepatic and hematological parameters of Africaninfants[J]. AIDS.2002,16(6):851-8.
[60] Shapiro RL, Ndung'u T, Lockman S, et al. Highly activeantiretroviral therapy started during pregnancy or postpartumsuppresses HIV-1RNA, but not DNA, in breast milk[J]. TheJournal of infectious diseases.2005,192(5):713-9.
[61] European Collaborative Study. Maternal factors and levels oftotal lymphocyte, CD4and CD8counts in uninfected childrenborn to HIV-1-infected mothers[J]. AIDS.2005,19(10):1071-9.
[62] Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatalantiretroviral drug exposure on hematologic values inHIV-uninfected children: An analysis of the women and infantstransmission study[J]. The Journal of infectious diseases.2006,194(8):1089-97.
[63] Reisler RB, Han C, Burman WJ, et al. Grade4events are asimportant as AIDS events in the era of HAART[J]. J AcquirImmune Defic Syndr.2003,34(4):379-86.
[64] Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemiain human immunodeficiency virus (HIV)-infected persons:results from the multistate adult and adolescent spectrum of HIVdisease surveillance project[J]. Blood.1998,91(1):301-8.
[65] Freund YR, Dousman L, MacGregor JT, et al. Oral treatmentwith trimethoprim-sulfamethoxazole and zidovudine suppressesmurine accessory cell-dependent immune responses[J].Toxicological sciences: an official journal of the Society ofToxicology.2000,55(2):335-42.
[66]郭学鹏,刘玉峰,王家勤.儿童白细胞缺乏症[J].实用儿科临床杂志.1993(03):134-8.
[67] Ziske J, Kunz A, Sewangi J, et al. Hematological changes inwomen and infants exposed to an AZT-containing regimen forprevention of mother-to-child-transmission of HIV in Tanzania[J].PloS one.2013,8(2):e55633.
[68] Bruel H, Chabrolle JP, el Khoury E, et al.[Thrombocytosis andcholestasis in a newborn treated with zidovudine][J]. Archives depediatrie: organe officiel de la Societe francaise de pediatrie.2001,8(8):893-4.
[69] Miguez-Burbano MJ, Burbano X, Rodriguez A, et al.Development of thrombocytosis in HIV+drug users: impact ofantiretroviral therapy[J]. Platelets.2002,13(3):183-5.
[70] Obladen M, Diepold K, Maier RF. Venous and arterialhematologic profiles of very low birth weight infants. EuropeanMulticenter rhEPO Study Group[J]. Pediatrics.2000,106(4):707-11.
[1] Cheng T. Toward 'SMART' stem cells[J]. Gene therapy.2008,15(2):67-73.
[2] Cabrita GJ, Ferreira BS, da Silva CL, et al. Hematopoietic stemcells: from the bone to the bioreactor[J]. Trends in biotechnology.2003,21(5):233-40.
[3] Forsberg EC, Bhattacharya D, Weissman IL. Hematopoietic stemcells: expression profiling and beyond[J]. Stem cell reviews.2006,2(1):23-30.
[4] McNamara LA, Ganesh JA, Collins KL. Latent HIV-1infectionoccurs in multiple subsets of hematopoietic progenitor cells and isreversed by NF-kappaB activation[J]. Journal of virology.2012,86(17):9337-50.
[5] Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al.Perinatal antiretroviral treatment and hematopoiesis inHIV-uninfected infants[J]. AIDS.2003,17(14):2053-61.
[6] Shah MM, Li Y, Christensen RD. Effects of perinatal zidovudineon hematopoiesis: a comparison of effects on progenitors fromhuman fetuses versus mothers[J]. AIDS.1996,10(11):1239-47.
[7] Connor EM, Sperling RS, Gelber R. Reduction of maternal infanttransmission of human immunodeficiency virus type1withzidovudine treatment.Pediatric AIDS Clinical Trials GroupProtocol076Study Group[J]. N Engl Med.1994,331(18):1173-80.
[8]王临虹.艾滋病病毒感染孕产妇治疗及预防艾滋病母婴传播抗病毒药物使用手册[M].北京:人民卫生出版社;2007.1-2.
[9] European Collaborative Study. Levels and patterns of neutrophilcell counts over the first8years of life in children of HIV-1infected mothers[J]. AIDS,2004,18(15):2009-17.
[10]刘景生,张均田.干细胞生物学[M].北京:化学工业出版社;2004.249-60.
[11] Christians U, Gottschalk S, Miljus J, et al. Alterations in glucosemetabolism by cyclosporine in rat brain slices link to oxidativestress: interactions with mTOR inhibitors[J]. British journal ofpharmacology.2004,143(3):388-96.
[12] Lim SE, Copeland WC. Differential incorporation and removal ofantiviral deoxynucleotides by human DNA polymerase gamma[J].The Journal of biological chemistry.2001,276(26):23616-23.
[13] Walker UA, Venhoff N, Koch EC, et al. Uridine abrogatesmitochondrial toxicity related to nucleoside analogue reversetranscriptase inhibitors in HepG2cells[J]. Antiviral therapy.2003,8(5):463-70.
[14] Eriksson S, Xu B, Clayton DA. Efficient incorporation of anti-HIVdeoxynucleotides by recombinant yeast mitochondrial DNApolymerase[J]. The Journal of biological chemistry.1995,270(32):18929-34.
[15] McComsey G, Bai RK, Maa JF, et al. Extensive investigations ofmitochondrial DNA genome in treated HIV-infected subjects:beyond mitochondrial DNA depletion[J]. J Acquir Immune DeficSyndr.2005,39(2):181-8.
[16] Lewis LD, Amin S, Civin CI, et al. Ex vivo zidovudine (AZT)treatment of CD34+bone marrow progenitors causes decreasedsteady state mitochondrial DNA (mtDNA) and increased lactateproduction[J]. Human&experimental toxicology.2004,23(4):173-85.
[17] Gogu SR, Beckman BS, Agrawal KC. Amelioration ofzidovudine-induced fetal toxicity in pregnant mice[J].Antimicrobial agents and chemotherapy.1992,36(11):2370-4.
[18] Gallicchio VS, Hughes NK. Suppression of murine hematopoiesisin vivo after chronic administration of zidovudine: evidence thatzidovudine-induced anemia is the result of decreased bonemarrow-derived, erythropoietin-responsive progenitor cells[J].Proc Soc Exp Biol Med.1992,199(4):459-65.
[19] Gallicchio VS, Hughes NK, Hulette BC. In vitro modulation of thetoxicity associated with the use of zidovudine on normal murine,human, and murine retrovirus-infected hematopoietic progenitorstem cells with basic fibroblast growth factor and synergisticactivity with interleukin-1[J]. Journal of leukocyte biology.1992,51(4):336-42.
[20] Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatalantiretroviral drug exposure on hematologic values inHIV-uninfected children: An analysis of the women and infantstransmission study[J]. The Journal of infectious diseases.2006,194(8):1089-97.
[21] Maida I, Nunez M, Rios MJ, et al. Severe liver disease associatedwith prolonged exposure to antiretroviral drugs[J]. J AcquirImmune Defic Syndr.2006,42(2):177-82.
[22] Floridia M, Tamburrini E, Ravizza M, et al. Antiretroviral therapyat conception in pregnant women with HIV in Italy: wide range ofvariability and frequent exposure to contraindicated drugs[J].Antiviral therapy.2006,11(7):941-6.
[23] Fang JL, Beland FA. Long-term exposure to zidovudine delays cellcycle progression, induces apoptosis, and decreases telomeraseactivity in human hepatocytes[J]. Toxicological sciences: anofficial journal of the Society of Toxicology.2009,111(1):120-30.
[24] Singh A, Hemal A, Agarwal S, et al. A prospective study ofhaematological changes after switching from stavudine tozidovudine-based antiretroviral treatment in HIV-infectedchildren[J]. International journal of STD&AIDS.2014.
[25] Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartumantiretroviral regimens to prevent intrapartum HIV infection[J].The New England journal of medicine.2012,366(25):2368-79.
[1] Forsberg EC, Bhattacharya D, Weissman IL. Hematopoietic stemcells: expression profiling and beyond[J]. Stem cell reviews.2006,2(1):23-30.
[2] Ezoe S, Matsumura I, Satoh Y, et al. Cell cycle regulation inhematopoietic stem/progenitor cells[J]. Cell Cycle.2004,3(3):314-8.
[3] Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versusdifferentiation[J]. Wiley interdisciplinary reviews Systems biologyand medicine.2010,2(6):640-53.
[4] Asnaghi L, Bruno P, Priulla M, et al. mTOR: a protein kinaseswitching between life and death[J]. Pharmacological research: theofficial journal of the Italian Pharmacological Society.2004,50(6):545-9.
[5] Holz MK, Blenis J. Identification of S6kinase1as a novelmammalian target of rapamycin (mTOR)-phosphorylatingkinase[J]. The Journal of biological chemistry.2005,280(28):26089-93.
[6] Adjei AA, Hidalgo M. Intracellular signal transduction pathwayproteins as targets for cancer therapy[J]. Journal of clinicaloncology: official journal of the American Society of ClinicalOncology.2005,23(23):5386-403.
[7] Hay N, Sonenberg N. Upstream and downstream of mTOR[J].Genes&development.2004,18(16):1926-45.
[8] Mansure JJ, Nassim R, Chevalier S, et al. Inhibition of mammaliantarget of rapamycin as a therapeutic strategy in the management ofbladder cancer[J]. Cancer biology&therapy.2009,8(24):2339-47.
[9] Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy ofcancer with rapamycin derivatives[J]. Annals of oncology: officialjournal of the European Society for Medical Oncology/ESMO.2005,16(4):525-37.
[10] Inoki K, Li Y, Zhu T, et al. TSC2is phosphorylated and inhibitedby Akt and suppresses mTOR signalling[J]. Nature cell biology.2002,4(9):648-57.
[11] Xu G, Zhang W, Bertram P, et al. Pharmacogenomic profiling ofthe PI3K/PTEN-AKT-mTOR pathway in common humantumors[J]. International journal of oncology.2004,24(4):893-900.
[12] Wolfram. Update on mTOR Inhibitors in Metastatic Renal Cancer.2007; Available from: http://www.medscape.org/viewarticle/559830.
[13] Heesom KJ, Denton RM. Dissociation of the eukaryotic initiationfactor-4E/4E-BP1complex involves phosphorylation of4E-BP1byan mTOR-associated kinase[J]. FEBS letters.1999,457(3):489-93.
[14] Hoeffer CA, Klann E. mTOR signaling: at the crossroads ofplasticity, memory and disease[J]. Trends in neurosciences.2010,33(2):67-75.
[15] Wendel HG, De Stanchina E, Fridman JS, et al. Survival signallingby Akt and eIF4E in oncogenesis and cancer therapy[J]. Nature.2004,428(6980):332-7.
[16] Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressorfrom human chromosome10q23, is a dual-specificityphosphatase[J]. Proceedings of the National Academy of Sciencesof the United States of America.1997,94(17):9052-7.
[17] Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration,spreading, and focal adhesions by tumor suppressor PTEN[J].Science.1998,280(5369):1614-7.
[18] Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependencedistinguishes haematopoietic stem cells from leukaemia-initiatingcells[J]. Nature.2006,441(7092):475-82.
[19] Duronio V, Scheid MP, Ettinger S. Downstream signalling eventsregulated by phosphatidylinositol3-kinase activity[J]. Cellularsignalling.1998,10(4):233-9.
[20] Jiang BH, Zheng JZ, Aoki M, et al. Phosphatidylinositol3-kinasesignaling mediates angiogenesis and expression of vascularendothelial growth factor in endothelial cells[J]. Proceedings of theNational Academy of Sciences of the United States of America.2000,97(4):1749-53.
[21] Peponi E, Drakos E, Reyes G, et al. Activation of mammaliantarget of rapamycin signaling promotes cell cycle progression andprotects cells from apoptosis in mantle cell lymphoma[J]. TheAmerican journal of pathology.2006,169(6):2171-80.
[22] Montiel-Duarte C, Cordeu L, Agirre X, et al. Resistance toImatinib Mesylate-induced apoptosis in acute lymphoblasticleukemia is associated with PTEN down-regulation due topromoter hypermethylation[J]. Leukemia research.2008,32(5):709-16.
[23] Yang J, Liu J, Zheng J, et al. A reappraisal by quantitative flowcytometry analysis of PTEN expression in acute leukemia[J].Leukemia.2007,21(9):2072-4.
[24] Chen C, Liu Y, Zheng P. mTOR regulation and therapeuticrejuvenation of aging hematopoietic stem cells[J]. Sciencesignaling.2009,2(98):ra75.
[25] Janzen V, Forkert R, Fleming HE, et al. Stem-cell ageing modifiedby the cyclin-dependent kinase inhibitor p16INK4a[J]. Nature.2006,443(7110):421-6.
[26] van Lohuizen M, Frasch M, Wientjens E, et al. Sequence similaritybetween the mammalian bmi-1proto-oncogene and the Drosophilaregulatory genes Psc and Su(z)2[J]. Nature.1991,353(6342):353-5.
[27] Park IK, Qian D, Kiel M, et al. Bmi-1is required for maintenanceof adult self-renewing haematopoietic stem cells[J]. Nature.2003,423(6937):302-5.
[28] Hanson RD, Hess JL, Yu BD, et al. Mammalian Trithorax andpolycomb-group homologues are antagonistic regulators ofhomeotic development[J]. Proceedings of the National Academy ofSciences of the United States of America.1999,96(25):14372-7.
[29] Park IK, He Y, Lin F, et al. Differential gene expression profiling ofadult murine hematopoietic stem cells[J]. Blood.2002,99(2):488-98.
[30] Lessard J, Sauvageau G. Bmi-1determines the proliferativecapacity of normal and leukaemic stem cells[J]. Nature.2003,423(6937):255-60.
[31] Raaphorst FM. Self-renewal of hematopoietic and leukemic stemcells: a central role for the Polycomb-group gene Bmi-1[J]. Trendsin immunology.2003,24(10):522-4.
[32] Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal ofhematopoietic stem cells mediated by the polycomb gene productBmi-1[J]. Immunity.2004,21(6):843-51.
[33] Molofsky AV, He S, Bydon M, et al. Bmi-1promotes neural stemcell self-renewal and neural development but not mouse growthand survival by repressing the p16Ink4a and p19Arf senescencepathways[J]. Genes&development.2005,19(12):1432-7.
[34] Jacobs JJ, Scheijen B, Voncken JW, et al. Bmi-1collaborates withc-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis viaINK4a/ARF[J]. Genes&development.1999,13(20):2678-90.
[35] Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, andcancer stem cells[J]. Nature.2001,414(6859):105-11.
[36] Oh W, Kim DS, Yang YS, et al. Immunological properties ofumbilical cord blood-derived mesenchymal stromal cells[J].Cellular immunology.2008,251(2):116-23.
[1] Connor EM, Sperling RS, Gelber R. Reduction of maternal infanttransmission of human immunodeficiency virus type1withzidovudine treatment.Pediatric AIDS Clinical Trials GroupProtocol076Study Group[J]. N Engl Med.1994,331(18):1173-80.
[2] WHO, UNAIDS, UNICEF. Towards universal access: scaling uppriority HIV/AIDS interventions in the health sector[J]. WorldHealth Organization. September28,2010
[3] WHO. Antiretroviral drugs for treating pregnant women andpreventing HIV infection in infants.2010; Available from:http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/.
[4]王爱霞,王福祥,毛青, et al.艾滋病诊疗指南.中华医学会第五次全国艾滋病、病毒性丙型肝炎暨全国热带病学术会议.2011:22
[5] Mirochnick M. Antiretroviral pharmacology in pregnant womenand their newborns[J]. Annals of the New York Academy ofSciences.2000,918:287-97.
[6] Public Health Service Task Force.Safety and toxicity of individualantiretroviral agents in pregnancy: supplement toPHSTFrecommendations for use of antiretroviral drugs in intervenpregnant HIV-1infected women for maternal health andinterventions to reduce perinatal HIV-1transmission in theUnitedStates2006[online].[cited2006Oct17]; Available from:http:\\aidsinfo.nih.gov.
[7] Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passageof protease inhibitors at delivery[J]. AIDS.2002,16(6):889-93.
[8] Chappuy H, Treluyer JM, Rey E, et al. Maternal-fetal transfer andamniotic fluid accumulation of protease inhibitors in pregnantwomen who are infected with human immunodeficiency virus[J].Am J Obstet Gynecol.2004,191(2):558-62.
[9] Important change in Sustiva (efavirenz) package insert: change from category C to D,March2005. Bristol-Myers Squibb Company [Internet].2006(Oct24). Available from: http://www.f-da.gov/medwatch/SAFETY/2005/Sustiva_DHCPletter-061005.pdf.
[10] Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartumantiretroviral regimens to prevent intrapartum HIV infection[J].The New England journal of medicine.2012,366(25):2368-79.
[11] Recommendations for Use of Antiretroviral Drugs in PregnantHIV-1-Infected Women for Maternal Health and Interventions toReduce Perinatal HIV Transmission in the United States.Developed by the HHS Panel on Treatment of HIV-InfectedWorking Group of the Office of AIDS Research Advisory Council(OARAC)[Internet].2011. Available from:http://aidsinfo.nih.gov/guidelines.
[12] Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load,zidovudine treatment, and the risk of transmission of humanimmunodeficiency virus type1from mother to infant. PediatricAIDS Clinical Trials Group Protocol076Study Group[J]. The NewEngland journal of medicine.1996,335(22):1621-9.
[13] Cooper ER, Charurat M, Mofenson L, et al. Combinationantiretroviral strategies for the treatment of pregnantHIV-1-infected women and prevention of perinatal HIV-1transmission[J]. J Acquir Immune Defic Syndr.2002,29(5):484-94.
[14]王临虹,方利文,王前, et al.我国艾滋病母婴传播水平传播时期及干预效果研究[J].中国艾滋病性病.2008(05):435-8.
[15]王临虹.艾滋病病毒感染孕产妇治疗及预防艾滋病母婴传播抗病毒药物使用手册[M].北京:人民卫生出版社;2007.1-2.
[16] McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-courseAZT plus3TC to reduce nevirapine resistance in the prevention ofmother-to-child HIV transmission: a randomized clinical trial[J].PLoS Med.2009,6(10):e1000172.
[17] Meda N, Leroy V, Viho I, et al. Field acceptability andeffectiveness of the routine utilization of zidovudine to reducemother-to-child transmission of HIV-1in West Africa[J]. AIDS.2002,16(17):2323-8.
[18]中国疾病预防控制中心性病艾滋病预防控制中心.卫生计生委:1至9月新发现艾滋病病毒感染者约7万例2013[cited201312-01]; Available from: http://www.chinaids.org.cn/jkjy/sjazbr1/rdgz1/201312/t20131201_90833.htm.
[19]中国疾病预防控制中心性病艾滋病预防控制中心.2011年中国艾滋病疫情估计[J].中国艾滋病性病.2012(01):1-5.
[20]中华人民共和国国家卫生和计划生育委员会.我国艾滋病防控工作背景2013[cited201311-30]; Available from:http://www.nhfpc.gov.cn/jkj/s3586/201312/2b871ccd2ef446eb9542875d3d68bbca.shtml.
[21] Antiretroviral Pregnancy Registry Steering Committee.Antiretroviral Pregnancy Registry International interim report for1January1989-31July2010[J]. Antiviral Pregnancy Registry.2010July
[22] Saitoh A, Hull AD, Franklin P, et al. Myelomeningocele in aninfant with intrauterine exposure to efavirenz[J]. Journal ofperinatology: official journal of the California PerinatalAssociation.2005,25(8):555-6.
[23] Watts DH. Teratogenicity risk of antiretroviral therapy inpregnancy[J]. Curr HIV/AIDS Rep.2007,4(3):135-40.
[24] Ford N, Calmy A, Mofenson L. Safety of efavirenz in the firsttrimester of pregnancy: an updated systematic review andmeta-analysis[J]. AIDS.2011,25(18):2301-4.
[25] Brogly SB, Abzug MJ, Watts DH, et al. Birth defects amongchildren born to human immunodeficiency virus-infected women:pediatric AIDS clinical trials protocols219and219C[J]. ThePediatric infectious disease journal.2010,29(8):721-7.
[26] Townsend Cl, Cortina BM, Peckham CS, et al. Low rates ofmotherto-child transmission of HIV following effective pregnancyinterventions in the United Kingdom and Ireland,2000-2006[J].AIDS.2008,22(8):973-81.
[27] Townsend CL, Willey BA, Cortina-Borja M, et al. Antiretroviraltherapy and congenital abnormalities in infants born toHIV-infected women in the UK and Ireland,1990-2007[J]. AIDS.2009,23(4):519-24.
[28] Townsend CL, Tookey PA, Cortina-Borja M, et al. Antiretroviraltherapy and congenital abnormalities in infants born toHIV-1-infected women in the United Kingdom and Ireland,1990to2003[J]. J Acquir Immune Defic Syndr.2006,42(1):91-4.
[29] European Collaborative Study. Does highly active antiretroviraltherapy increase the risk of congenital abnormalities in HIVinfected women?[J]. Acquir Immune Defic Syndr.2005,40(1):116-8.
[30] Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infantoutcomes among HIV-infected women taking long-term ART withand without tenofovir in the DART trial[J]. PLoS Med.2012,9(5):e1001217.
[31] Tariq S, Thorne C, Townsend C. Pregnancy outcomes in HIVinfected women using non-zidovudine HAART in Europe:2000to2009[895].17th Conference on Retroviruses and OpportunisticInfections; San Francisco2010.
[32] Jungmann EM, Mercey D, DeRuiter A, et al. Is first trimesterexposure to the combination of antiretroviral therapy and folateantagonists a risk factor for congenital abnormalities?[J]. Sexuallytransmitted infections.2001,77(6):441-3.
[33] Forna F, McConnell M, Kitabire FN, et al. Systematic review ofthe safety of trimethoprim-sulfamethoxazole for prophylaxis inHIV-infected pregnant women: implications for resource-limitedsettings[J]. AIDS reviews.2006,8(1):24-36.
[34] European Collaborative Study. Exposure to antiretroviral therapy inutero or early life: the health of uninfected children born toHIV-infected women[J]. Acquir Immune Defic Syndr.2003,32(4):380-7.
[35] Taha TE KN, Gibbons A, et al. Effect of HIV-1antiretroviralprophylaxis on hepatic and hematological parameters of Africaninfants[J]. AIDS.2002,16(6):851-8.
[36] Shapiro RL, Ndung'u T, Lockman S, et al. Highly activeantiretroviral therapy started during pregnancy or postpartumsuppresses HIV-1RNA, but not DNA, in breast milk[J]. TheJournal of infectious diseases.2005,192(5):713-9.
[37] Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al.Perinatal antiretroviral treatment and hematopoiesis inHIV-uninfected infants[J]. AIDS.2003,17(14):2053-61.
[38] Nielsen-Saines K, Watts D H, VG V. Three postpartumantiretroviralregimens to prevent intrapartum HIV infection[J]. TheNew England journal of medicine.2012,366(25):2368-79.
[39] The Perinatal Safety Review Working G. Nucleoside exposure inthe children of HIV-infected women receiving antiretroviral drugs:absence of clear evidence for mitochondrial disease in childrenwho died before5years of age in fiv United States cohorts[J]. JAcquir Immune Defi Syndr.2000,25(3):261-8.
[40] European Collaborative Study. Levels and patterns of neutrophilcell counts over the first8years of life in children of HIV-1infected mothers[J]. AIDS.2004,18(15):2009-17.
[41] Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematologicalparameters of HIV-1-uninfected infants born to HIV-1-infectedmothers[J]. Acta Paediatr.2005,94(11):1571-7.
[42] Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatalantiretroviral drug exposure on hematologic values inHIV-uninfected children: An analysis of the women and infantstransmission study[J]. The Journal of infectious diseases.2006,194(8):1089-97.
[43] Feiterna-Sperling C, Weizsaecker K, Buhrer C, et al. Hematologiceffects of maternal antiretroviral therapy and transmissionprophylaxis in HIV-1-exposed uninfected newborn infants[J]. JAcquir Immune Defic Syndr.2007,45(1):43-51.
[44] Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infantantiretroviral drugs to reduce HIV-1transmission[J]. The NewEngland journal of medicine.2010,362(24):2271-81.
[45] The Kesho Bora Study Group. Triple antiretroviral compared withzidovudine and single-dose nevirapine prophylaxis duringpregnancy and breastfeeding for prevention of mother-to-childtransmission of HIV-1(Kesho Bora study): a randomisedcontrolled trial[J]. The Lancet infectious diseases.2011,11(3):171-80.
[46] Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens inpregnancy and breast-feeding in Botswana[J]. The New Englandjournal of medicine.2010,362(24):2282-94.
[47] Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased riskof severe infant anemia after exposure to maternal HAART,Botswana[J]. J Acquir Immune Defic Syndr.2011,56(5):428-36.
[48] Bae WH, Wester C, Smeaton LM, et al. Hematologic and hepatictoxicities associated with antenatal and postnatal exposure tomaternal highly active antiretroviral therapy among infants[J].AIDS.2008,22(13):1633-40.
[49] Toltzis P, Marx CM, Kleinman N, et al. Zidovudine-associatedembryonic toxicity in mice[J]. The Journal of infectious diseases.1991,163(6):1212-8.
[50] Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacentalgenotoxicity of combined antiretroviral nucleoside analoguetherapy in Erythrocebus patas monkeys[J]. J Acquir Immune DeficSyndr.2002,29(4):323-9.
[51] Brogly S, Williams P. In utero nucleoside reverse transcriptaseinhibitor exposure and cancer in HIV-uninfected children: anupdate from the pediatric AIDS clinical trials group219and219Ccohorts[J]. J Acquir Immune Defic Syndr.2006,41(4):535-6.
[52] Oleske JM. Long-term outcomes in infants born to HIV-infectedwomen[J]. J Acquir Immune Defic Syndr.2003,32(4):353.
[53] Poirier MC, Olivero OA, Walker DM, et al. Perinatal genotoxicityand carcinogenicity of anti-retroviral nucleoside analog drugs[J].Toxicology and applied pharmacology.2004,199(2):151-61.
[54] Combination antiretroviral therapy and duration of pregnancy[J].AIDS.2000,14(18):2913-20.
[55] Thorne C, Patel D, Newell ML. Increased risk of adversepregnancy outcomes in HIV-infected women treated with highlyactive antiretroviral therapy in Europe[J]. AIDS.2004,18(17):2337-9.
[56] Townsend CL, Cortina-Borja M, Peckham CS, et al. Antiretroviraltherapy and premature delivery in diagnosed HIV-infected womenin the United Kingdom and Ireland[J]. AIDS.2007,21(8):1019-26.
[57] Chiesa E, Repetto D, Melzi S. Increasing risk of preterm deliverywith more potent antiretroviral therapy (ART)Increasing risk ofpreterm delivery with more potent antiretroviral therapy (ART).
[M]: The Gardiner-Caldwell Group Ltd,Tytherington, Cheshire,UK;2007.
[58] Boer K, Nellen JF, Patel D, et al. The AmRo study: pregnancyoutcome in HIV-1-infected women under effective highly activeantiretroviral therapy and a policy of vaginal delivery[J]. BJOG:an international journal of obstetrics and gynaecology.2007,114(2):148-55.
[59] Grosch-Woerner I, Puch K, Maier RF, et al. Increased rate ofprematurity associated with antenatal antiretroviral therapy in aGerman/Austrian cohort of HIV-1-infected women[J]. HIVmedicine.2008,9(1):6-13.
[60] Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note ofcaution[J]. The Journal of infectious diseases.2012,206(11):1639-41.
[61] Ndirangu J, Newell ML, Bland RM, et al. Maternal HIV infectionassociated with small-for-gestational age infants but not pretermbirths: evidence from rural South Africa[J]. Hum Reprod.2012,27(6):1846-56.
[62] Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviraltherapy and adverse birth outcomes among HIV-infected women inBotswana[J]. The Journal of infectious diseases.2012,206(11):1695-705.
[63] Darak S, Darak T, Kulkarni S, et al. Effect of highly activeantiretroviral treatment (HAART) during pregnancy on pregnancyoutcomes: experiences from a PMTCT program in western India[J].AIDS patient care and STDs.2013,27(3):163-70.
[64] Bera E MR. Safety of nevirapine in HIV-infected pregnant womeninitiating antiretroviral therapy at higher CD4counts: a systematicreview and meta analysis[J]. South Afr Med J.2012,102(11pt1):855-9.
[65] Jones CE, Naidoo S, De Beer C, et al. Maternal HIV infection andantibody responses against vaccine-preventable diseases inuninfected infants[J]. JAMA: the journal of the American MedicalAssociation.2011,305(6):576-84.
[66] Miles DJ, Gadama L, Gumbi A, et al. Human immunodeficiencyvirus (HIV) infection during pregnancy induces CD4T-celldifferentiation and modulates responses to Bacille Calmette-Guerin(BCG) vaccine in HIV-uninfected infants[J]. Immunology.2010,129(3):446-54.
[67] Slogrove AL, Cotton MF, Esser MM. Severe infections inHIV-exposed uninfected infants: clinical evidence ofimmunodeficiency[J]. Journal of tropical pediatrics.2010,56(2):75-81.
[68] Gompels UA, Larke N, Sanz-Ramos M, et al. Humancytomegalovirus infant infection adversely affects growth anddevelopment in maternally HIV-exposed and unexposed infants inZambia[J]. Clinical infectious diseases: an official publication ofthe Infectious Diseases Society of America.2012,54(3):434-42.
[69] Karpelowsky JS, Millar AJ, van der Graaf N, et al. Comparison ofin-hospital morbidity and mortality in HIV-infected and uninfectedchildren after surgery[J]. Pediatric surgery international.2012,28(10):1007-14.
[70] Karpelowsky JS, Leva E, Kelley B, et al. Outcomes of humanimmunodeficiency virus-infected and-exposed childrenundergoing surgery--a prospective study[J]. Journal of pediatricsurgery.2009,44(4):681-7.
[71] Karpelowsky JS, Millar AJ, van der Graaf N, et al. Outcome ofHIV-exposed uninfected children undergoing surgery[J]. BMCpediatrics.2011,11:69.
[72] Hankin C, Thorne C, Newell ML. Does exposure to antiretroviraltherapy affect growth in the first18months of life in uninfectedchildren born to HIV-infected women?[J]. J Acquir Immune DeficSyndr.2005,40(3):364-70.
[73] Powis KM, Smeaton L, Ogwu A, et al. Effects of in uteroantiretroviral exposure on longitudinal growth of HIV-exposeduninfected infants in Botswana[J]. J Acquir Immune Defic Syndr.2011,56(2):131-8.
[74] Williams PL, Marino M, Malee K, et al. Neurodevelopment and inutero antiretroviral exposure of HIV-exposed uninfected infants[J].Pediatrics.2010,125(2):e250-60.
[75] Lattner J, Soclas ME, Buraschi M F. Growth andneurodevelopment in HIV-uninfected children born fromHIV-infected women in a public general hospital from Argentina
[WEPE0145]. Paper presented at: XVIII International AIDSConference. Vienna2010.
[76] Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia,antiretroviral therapy, and immune reconstitution[J]. Lancet.2002,360(9340):1152-4.
[77] Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsiaand fetal death in HIV-infected pregnant women receiving highlyactive antiretroviral therapy[J]. AIDS.2006,20(1):59-66.
[78] Flint OP, Noor MA, Hruz PW, et al. The role of protease inhibitorsin the pathogenesis of HIV-associated lipodystrophy: cellularmechanisms and clinical implications[J]. Toxicologic pathology.2009,37(1):65-77.
[79] Grinspoon S, Carr A. Cardiovascular risk and body-fatabnormalities in HIV-infected adults[J]. The New England journalof medicine.2005,352(1):48-62.
[80] Jones R, Sawleshwarkar S, Michailidis C, et al. Impact ofantiretroviral choice on hypercholesterolaemia events: the role ofthe nucleoside reverse transcriptase inhibitor backbone[J]. HIVmedicine.2005,6(6):396-402.
[81] Stanley TL, Grinspoon SK. Body composition and metabolicchanges in HIV-infected patients[J]. The Journal of infectiousdiseases.2012,205Suppl3:S383-90.
[82] Dimock D, Thomas V, Cushing A, et al. Longitudinal assessmentof metabolic abnormalities in adolescents and young adults withHIV-infection acquired perinatally or in early childhood[J].Metabolism: clinical and experimental.2011,60(6):874-80.
[83] Hazra R, Cohen RA, Gonin R. Lipid levels in the second year oflife among HIV-infected and HIV-exposed uninfected LatinAmerican children[J]. AIDS.2012,26(2):235-40.
[84] Woollett LA. Maternal cholesterol in fetal development: transportof cholesterol from the maternal to the fetal circulation[J]. TheAmerican journal of clinical nutrition.2005,82(6):1155-61.
[85] Senise JF, Castelo A, Martinez M. Current treatment strategies,complications and considerations for the use of HIV antiretroviraltherapy during pregnancy[J]. AIDS reviews.2011,13(4):198-213.
[86] Mudd LM HC, Catov JM,Senagore PK, Evans RW. Maternal lipidsat mid-pregnancy and the risk of preterm delivery[J]. Acta ObstetGynecol Scand.2012,91(6):726-35.
[87] Tien PC, Schneider MF, Cox C, et al. Association of HIV infectionwith incident diabetes mellitus: impact of using hemoglobin A1Cas a criterion for diabetes[J]. J Acquir Immune Defic Syndr.2012,61(3):334-40.
[88] Geffner ME, Patel K, Miller TL, et al. Factors associated withinsulin resistance among children and adolescents perinatallyinfected with HIV-1in the pediatric HIV/AIDS cohort study[J].Horm Res Paediatr.2011,76(6):386-91.
[89] Gutierrez AD, Balasubramanyam A. Dysregulation of glucosemetabolism in HIV patients: epidemiology, mechanisms, andmanagement[J]. Endocrine.2012,41(1):1-10.
[90] Watts DH, Balasubramanian R, Maupin RT. Maternal toxicity andpregnancy complications in HIV-infected women receivingantiretroviral therapy: an analysis of the PACTG316Study[J]. AmJ Obstet Gynecol.2004,190(2):506-16.
[91] Teissier R, Nowak E, Assoun M, et al. Maternal phenylketonuria:low phenylalaninemia might increase the risk of intra uterinegrowth retardation[J]. J Inherit Metab Dis.2012,35(6):993-9.
[92] Apostolova N, Blas-Garcia A, Esplugues JV. Mitochondrialinterference by anti-HIV drugs: mechanisms beyond Pol-gammainhibition[J]. Trends in pharmacological sciences.2011,32(12):715-25.
[93] Chan SS, Santos JH, Meyer JN, et al. Mitochondrial toxicity inhearts of CD-1mice following perinatal exposure to AZT,3TC, orAZT/3TC in combination[J]. Environ Mol Mutagen.2007,48(3-4):190-200.
[94] Divi Rl, Leonard SL, Kuo MM, et al. Transplacentally exposedhuman and monkey newborn infants show similar evidence ofnucleoside reverse transcriptase inhibitor-induced mitochondrialtoxicity[J]. Environ Mol Mutagen.2007Apr-May,48(3-4):201-9.
[95] Heidari S, Mofenson L, Cotton MF, et al. Antiretroviral drugs forpreventing mother-to-child transmission of HIV: a review ofpotential effects on HIV-exposed but uninfected children[J]. JAcquir Immune Defic Syndr.2011,57(4):290-6.
[96] Miller TI, Borkowsky W, DiMeglio LA, et al. Metabolicabnormalities and viral replication are associated with biomarkersof vascular dysfunction in HIV-infected children[J]. HIV medicine.2012,13(5):264-75.
[97] Ross AC, Leong T, Avery A, et al. Effects of in utero antiretroviralexposure on mitochondrial DNA levels, mitochondrial function andoxidative stress[J]. HIV medicine.2012,13(2):98-106.
[98] Hernandez S, Moren C, Lopez M, et al. Perinatal outcomes,mitochondrial toxicity and apoptosis in HIV-treated pregnantwomen and in-utero-exposed newborn[J]. AIDS.2012,26(4):419-28.
[99] Brogly SB, Foca M, Deville JG, et al. Potential confounding of theassociation between exposure to nucleoside analogues andmitochondrial dysfunction in HIV-uninfected and indeterminateinfants[J]. J Acquir Immune Defic Syndr.2010,53(1):154-7.
[100] Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrialdysfunction in HIV-1-exposed but uninfected infants: clinicalscreening in a large prospective cohort[J]. AIDS.2003,17(12):1769-85.
[101] Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleosidereverse transcriptase inhibitor exposure and signs of possiblemitochondrial dysfunction in HIV-uninfected children[J]. AIDS.2007,21(8):929-38.
[102] Aldrovandi GM, Chu C, Shearer WT, et al. Antiretroviral exposureand lymphocyte mtDNA content among uninfected infants ofHIV-1-infected women[J]. Pediatrics.2009,124(6):e1189-97.
[103] Cote HC, Raboud J, Bitnun A, et al. Perinatal exposure toantiretroviral therapy is associated with increased bloodmitochondrial DNA levels and decreased mitochondrial geneexpression in infants[J]. The Journal of infectious diseases.2008,198(6):851-9.
[104] Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemiain human immunodeficiency virus-uninfected infants who areexposed to antiretrovirals[J]. Pediatrics.2004,114(5):e598-603.
[105] Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia inhuman immunodeficiency virus-uninfected infants exposed toperinatal antiretroviral therapy[J]. The Pediatric infectious diseasejournal.2003,22(9):782-9.
[106] Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels inchildren perinatally treated with antiretroviral agents to preventHIV transmission[J]. AIDS.2001,15(8):1074-5.
[107] Ekouevi DK, Toure R, Becquet R, et al. Serum lactate levels ininfants exposed peripartum to antiretroviral agents to preventmother-to-child transmission of HIV: Agence Nationale deRecherches Sur le SIDA et les Hepatites Virales1209study,Abidjan, Ivory Coast[J]. Pediatrics.2006,118(4):e1071-7.
[108] Blanche S. Possible long-term effect of in utero antiretroviralexposure?[J]. Archives de pediatrie: organe officiel de la Societefrancaise de pediatrie.2007,14(6):610-1.
[109] Foster C, Lyall H. HIV and mitochondrial toxicity in children[J].The Journal of antimicrobial chemotherapy.2008,61(1):8-12.
[2]中国疾病预防控制中心性病艾滋病预防控制中心.2013年11月全国艾滋病性病疫情及主要防治工作进展[J].中国艾滋病性病.2014(01):1.
[3]中华人民共和国国家卫生和计划生育委员会.我国艾滋病防控工作背景2013[cited201311-30]; Available from: http://www.nhfpc.gov.cn/jkj/s3586/201312/2b871ccd2ef446eb9542875d3d68bbca.shtml.
[4]王临虹,方利文,王前, et al.我国艾滋病母婴传播水平传播时期及干预效果研究[J].中国艾滋病性病.2008(05):435-8.
[5]王爱霞,王福祥,毛青, et al.艾滋病诊疗指南.中华医学会第五次全国艾滋病、病毒性丙型肝炎暨全国热带病学术会议.2011:22
[6]王临虹.艾滋病病毒感染孕产妇治疗及预防艾滋病母婴传播抗病毒药物使用手册[M].北京:人民卫生出版社;2007.1-2.
[7] Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartumantiretroviral regimens to prevent intrapartum HIV infection[J]. TheNew England journal of medicine.2012,366(25):2368-79.
[8] Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load,zidovudine treatment, and the risk of transmission of humanimmunodeficiency virus type1from mother to infant. Pediatric AIDSClinical Trials Group Protocol076Study Group[J]. The New Englandjournal of medicine.1996,335(22):1621-9.
[9] Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviralstrategies for the treatment of pregnant HIV-1-infected women andprevention of perinatal HIV-1transmission[J]. J Acquir Immune DeficSyndr.2002,29(5):484-94.
[10]中国疾病预防控制中心性病艾滋病预防控制中心.卫生计生委:1至9月新发现艾滋病病毒感染者约7万例2013[cited201312-01]; Available from: http://www.chinaids.org.cn/jkjy/sjazbr1/rdgz1/201312/t20131201_90833.htm.
[11]莫云,黄越华,李映.2007～2011年广西艾滋病及艾滋病病毒感染孕产妇死亡状况调查分析[J].中国临床新医学.2012(10):909-12.
[12]蒙春莲. HIV感染孕产妇HAART治疗对母婴传播的影响[J].广西医学.2011(11):1432-4.
[13]庞俊,黄绍标. HAART阻断HIV母婴传播效果观察[J].广西医学.2009(09):1254-5.
[14]刘冬梅,庞俊,韦淑珍, et al.不同孕期HIV/AIDS孕妇接受抗病毒治疗的效果评估[J].中华全科医学.2013(07):1061-2.
[15] Schramm DB, Meddows-Taylor S, Gray GE, et al. Low maternal viralloads and reduced granulocyte-macrophage colony-stimulating factorlevels characterize exposed, uninfected infants who develop protectivehuman immunodeficiency virus type1-specific responses[J]. Clinicaland vaccine immunology: CVI.2007,14(4):348-54.
[16] Mehta S, Hunter DJ, Mugusi FM, et al. Perinatal outcomes, includingmother-to-child transmission of HIV, and child mortality and theirassociation with maternal vitamin D status in Tanzania[J]. The Journalof infectious diseases.2009,200(7):1022-30.
[17] Cote HC, Raboud J, Bitnun A, et al. Perinatal exposure to antiretroviraltherapy is associated with increased blood mitochondrial DNA levelsand decreased mitochondrial gene expression in infants[J]. The Journalof infectious diseases.2008,198(6):851-9.
[1] UNAIDS. UNAIDS report on the global AIDS epidemic2013.2013; Available from: http://10.128.9.132/files/60780000000D7968/www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_
en.pdf.[2]中国疾病预防控制中心性病艾滋病预防控制中心.卫生计生委:1至9月新发现艾滋病病毒感染者约7万例2013[cited201312-01]; Available from: http://www.chinaids.org.cn/jkjy/sj
azbr1/rdgz1/201312/t20131201_90833.htm.[3]中华人民共和国国家卫生和计划生育委员会.我国艾滋病防控工作背景2013[cited201311-30]; Available from:http://www.nhfpc.gov.cn/jkj/s3586/201312/2b871ccd2ef446eb95
42875d3d68bbca.shtml.[4]王爱霞,王福祥,毛青, et al.艾滋病诊疗指南.中华医学会第五次全国艾滋病、病毒性丙型肝炎暨全国热带病学术会议.
2011:22[5] Important change in Sustiva (efavirenz) package insert: change from category C to D,March2005. Bristol-Myers Squibb Company [Internet].2006(Oct24). Available from: http://www.f-da.gov/medwatch/SAFETY/2005/Sustiva_DHCPletter-061005.pdf.
[6] Antiretroviral pregnancy registry international interim report for1January1989-31January2010. Antiretroviral PregnancyRegistry Steering Committee [Internet].2009. Available from:www.APRegistry.com.
[7] Recommendations for Use of Antiretroviral Drugs in PregnantHIV-1-Infected Women for Maternal Health and Interventions toReduce Perinatal HIV Transmission in the United States.Developed by the HHS Panel on Treatment of HIV-InfectedPregnant Women and Prevention of Perinatal Transmission-AWorking Group of the Office of AIDS Research AdvisoryCouncil (OARAC)[Internet].2011. Available from:http://aidsinfo.nih.gov/guidelines.
[8] Baroncelli S, Tamburrini E, Ravizza M, et al. Antiretroviraltreatment in pregnancy: a six-year perspective on recent trends inprescription patterns, viral load suppression, and pregnancyoutcomes[J]. AIDS patient care and STDs.2009,23(7):513-20.
[9] Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatmentof adult HIV infection:2010recommendations of theInternational AIDS Society-USA panel[J]. JAMA: the journal ofthe American Medical Association.2010,304(3):321-33.
[10] El Beitune P, Duarte G. Antiretroviral agents during pregnancy:consequences on hematologic parameters in HIV-exposed,uninfected newborn infant[J]. European journal of obstetrics,gynecology, and reproductive biology.2006,128(1-2):59-63.
[11] Feiterna-Sperling C, Weizsaecker K, Buhrer C, et al.Hematologic effects of maternal antiretroviral therapy andtransmission prophylaxis in HIV-1-exposed uninfected newborninfants[J]. J Acquir Immune Defic Syndr.2007,45(1):43-51.
[12] Baroncelli S, Pinnetti C, Genovese O, et al. Hematologicaleffects of zidovudine prophylaxis in newborn infants with andwithout prenatal exposure to zidovudine[J]. Journal of medicalvirology.2011,83(3):551-6.
[13] Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note ofcaution[J]. The Journal of infectious diseases.2012,206(11):1639-41.
[14] Ndirangu J, Newell ML, Bland RM, et al. Maternal HIVinfection associated with small-for-gestational age infants but notpreterm births: evidence from rural South Africa[J]. Hum Reprod.2012,27(6):1846-56.
[15]李爱杰,汪永忠. HIV感染妇女分娩婴儿低出生体质量情况及影响因素分析[J].中国皮肤性病学杂志.2013(02):161-2.
[16]金汉珍，黄德珉，官希吉.实用新生儿学[M].北京:人民卫生出版社.631.
[17]谢幸,苟文丽.妇产科学[M].北京:人民卫生出版社;2013.92.
[18]王前.抗逆转录病毒药物预防艾滋病母婴传播效果评价[博士]:中国疾病预防控制中心;2011:53.
[19]庞俊,黄绍标. HAART阻断HIV母婴传播效果观察[J].广西医学.2009(09):1254-5.
[20]蒙春莲. HIV感染孕产妇HAART治疗对母婴传播的影响[J].广西医学.2011(11):1432-4.
[21]李太生.艾滋病的免疫功能重建研究进展[J].传染病信息.2003(04):150-2.
[22] Smiatacz T.[Immune mechanisms in HIV infection and their rolein antiretroviral therapy][J]. Przeglad epidemiologiczny.2003,57(2):309-16.
[23] de Vincenzi I. Triple antiretroviral compared with zidovudine andsingle-dose nevirapine prophylaxis during pregnancy andbreastfeeding for prevention of mother-to-child transmission ofHIV-1(Kesho Bora study): a randomised controlled trial[J]. TheLancet infectious diseases.2011,11(3):171-80.
[24]张璐,王临虹,方利文.分娩方式与艾滋病母婴传播[J].中国艾滋病性病.2012(04):265-8.
[25] ACOG committee opinion scheduled Cesarean delivery and theprevention of vertical transmission of HIV infection. Number234,May2000(replaces number219, August1999)[J]. Internationaljournal of gynaecology and obstetrics: the official organ of theInternational Federation of Gynaecology and Obstetrics.2001,73(3):279-81.
[26] Machado ES, Hofer CB, Costa TT, et al. Pregnancy outcome inwomen infected with HIV-1receiving combination antiretroviraltherapy before versus after conception[J]. Sexually transmittedinfections.2009,85(2):82-7.
[27] Townsend CL, Cortina-Borja M, Peckham CS, et al.Antiretroviral therapy and premature delivery in diagnosedHIV-infected women in the United Kingdom and Ireland[J].AIDS.2007,21(8):1019-26.
[28] Kourtis AP, Schmid CH, Jamieson DJ, et al. Use of antiretroviraltherapy in pregnant HIV-infected women and the risk ofpremature delivery: a meta-analysis[J]. AIDS.2007,21(5):607-15.
[29] Briand N, Mandelbrot L, Le Chenadec J, et al. No relationbetween in-utero exposure to HAART and intrauterine growthretardation[J]. AIDS.2009,23(10):1235-43.
[30] Darak S, Darak T, Kulkarni S, et al. Effect of highly activeantiretroviral treatment (HAART) during pregnancy onpregnancy outcomes: experiences from a PMTCT program inwestern India[J]. AIDS patient care and STDs.2013,27(3):163-70.
[31] Parekh N, Ribaudo H, Souda S, et al. Risk factors for verypreterm delivery and delivery of very-small-for-gestational-ageinfants among HIV-exposed and HIV-unexposed infants inBotswana[J]. International journal of gynaecology and obstetrics:the official organ of the International Federation of Gynaecologyand Obstetrics.2011,115(1):20-5.
[32] Connor EM, Sperling RS, Gelber R. Reduction of maternal infanttransmission of human immunodeficiency virus type1withzidovudine treatment.Pediatric AIDS Clinical Trials GroupProtocol076Study Group[J]. N Engl Med.1994,331(18):1173-80.
[33] Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load,zidovudine treatment, and the risk of transmission of humanimmunodeficiency virus type1from mother to infant. PediatricAIDS Clinical Trials Group Protocol076Study Group[J]. TheNew England journal of medicine.1996,335(22):1621-9.
[34] Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al.Perinatal antiretroviral treatment and hematopoiesis inHIV-uninfected infants[J]. AIDS.2003,17(14):2053-61.
[35] Majluf-Cruz A, Luna-Castanos G, Trevino-Perez S, et al.Lamivudine-induced pure red cell aplasia[J]. American journal ofhematology.2000,65(3):189-91.
[36] Pluda JM, Cooley TP, Montaner JS, et al. A phase I/II study of2'-deoxy-3'-thiacytidine (lamivudine) in patients with advancedhuman immunodeficiency virus infection[J]. The Journal ofinfectious diseases.1995,171(6):1438-47.
[37] Marzolini C, Rudin C, Decosterd LA, et al. Transplacentalpassage of protease inhibitors at delivery[J]. AIDS.2002,16(6):889-93.
[38] Olagunju A, Owen A, Cressey TR. Potential effect ofpharmacogenetics on maternal, fetal and infant antiretroviral drugexposure during pregnancy and breastfeeding[J].Pharmacogenomics.2012,13(13):1501-22.
[39] Chappuy H, Treluyer JM, Jullien V, et al. Maternal-fetal transferand amniotic fluid accumulation of nucleoside analogue reversetranscriptase inhibitors in human immunodeficiencyvirus-infected pregnant women[J]. Antimicrobial agents andchemotherapy.2004,48(11):4332-6.
[40] Mirochnick M. Antiretroviral pharmacology in pregnant womenand their newborns[J]. Annals of the New York Academy ofSciences.2000,918:287-97.
[41] Kirmse B, Hobbs CV, Peter I, et al. Abnormal newborn screensand acylcarnitines in HIV-exposed and ARV-exposed infants[J].The Pediatric infectious disease journal.2013,32(2):146-50.
[42] Shah MM, Li Y, Christensen RD. Effects of perinatal zidovudineon hematopoiesis: a comparison of effects on progenitors fromhuman fetuses versus mothers[J]. AIDS.1996,10(11):1239-47.
[43] Huang SS, Barbour JD, Deeks SG, et al. Reversal of humanimmunodeficiency virus type1-associated hematosuppression byeffective antiretroviral therapy[J]. Clinical infectious diseases:an official publication of the Infectious Diseases Society ofAmerica.2000,30(3):504-10.
[44] Moore RD, Forney D. Anemia in HIV-infected patients receivinghighly active antiretroviral therapy[J]. J Acquir Immune DeficSyndr.2002,29(1):54-7.
[45] Berhane K, Karim R, Cohen MH, et al. Impact of highly activeantiretroviral therapy on anemia and relationship between anemiaand survival in a large cohort of HIV-infected women: Women'sInteragency HIV Study[J]. J Acquir Immune Defic Syndr.2004,37(2):1245-52.
[46]张时民.血常规中红细胞参数的诊断价值和意义[J].中国临床医生.2001(11):25-7.
[47] Lin CK, Lin JS, Chen SY, et al. Comparison of hemoglobin andred blood cell distribution width in the differential diagnosis ofmicrocytic anemia[J]. Archives of pathology&laboratorymedicine.1992,116(10):1030-2.
[48] Bessman JD, Gilmer PR, Jr., Gardner FH. Improvedclassification of anemias by MCV and RDW[J]. Americanjournal of clinical pathology.1983,80(3):322-6.
[49] Pinnetti C, Baroncelli S, Molinari A, et al. Common occurrenceof anaemia at the end of pregnancy following exposure tozidovudine-free regimens[J]. The Journal of infection.2011,63(2):144-50.
[50] European Collaborative Study. Exposure to antiretroviral therapyin utero or early life: the health of uninfected children born toHIV-infected women[J]. Acquir Immune Defic Syndr.2003,32(4):380-7.
[51] European Collaborative Study. Levels and patterns of neutrophilcell counts over the first8years of life in children of HIV-1infected mothers[J]. AIDS,18(15):2009-2017.2004,18(15):2009-17.
[52] Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increasedrisk of severe infant anemia after exposure to maternal HAART,Botswana[J]. J Acquir Immune Defic Syndr.2011,56(5):428-36.
[53] Steele RH, Keogh GL, Quin J, et al. Mean cell volume (MCV)changes in HIV-positive patients taking nucleoside reversetranscriptase inhibitors (NRTIs): a surrogate marker foradherence[J]. International journal of STD&AIDS.2002,13(11):748-54.
[54]王鸿利,顾荣泉,宁嗣宗.血液学及血液学检验[M].北京:人民卫生出版社;1997.
[55] Weiss G, Goodnough LT. Anemia of chronic disease[J]. The NewEngland journal of medicine.2005,352(10):1011-23.
[56] Friedman JS, Lopez MF, Fleming MD, et al. SOD2-deficiencyanemia: protein oxidation and altered protein expression revealtargets of damage, stress response, and antioxidantresponsiveness[J]. Blood.2004,104(8):2565-73.
[57] Evans TC, Jehle D. The red blood cell distribution width[J]. TheJournal of emergency medicine.1991,9Suppl1:71-4.
[58] Ferrucci L, Guralnik JM, Woodman RC, et al. Proinflammatorystate and circulating erythropoietin in persons with and withoutanemia[J]. The American journal of medicine.2005,118(11):1288.
[59] Taha TE KN, Gibbons A, et al. Effect of HIV-1antiretroviralprophylaxis on hepatic and hematological parameters of Africaninfants[J]. AIDS.2002,16(6):851-8.
[60] Shapiro RL, Ndung'u T, Lockman S, et al. Highly activeantiretroviral therapy started during pregnancy or postpartumsuppresses HIV-1RNA, but not DNA, in breast milk[J]. TheJournal of infectious diseases.2005,192(5):713-9.
[61] European Collaborative Study. Maternal factors and levels oftotal lymphocyte, CD4and CD8counts in uninfected childrenborn to HIV-1-infected mothers[J]. AIDS.2005,19(10):1071-9.
[62] Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatalantiretroviral drug exposure on hematologic values inHIV-uninfected children: An analysis of the women and infantstransmission study[J]. The Journal of infectious diseases.2006,194(8):1089-97.
[63] Reisler RB, Han C, Burman WJ, et al. Grade4events are asimportant as AIDS events in the era of HAART[J]. J AcquirImmune Defic Syndr.2003,34(4):379-86.
[64] Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemiain human immunodeficiency virus (HIV)-infected persons:results from the multistate adult and adolescent spectrum of HIVdisease surveillance project[J]. Blood.1998,91(1):301-8.
[65] Freund YR, Dousman L, MacGregor JT, et al. Oral treatmentwith trimethoprim-sulfamethoxazole and zidovudine suppressesmurine accessory cell-dependent immune responses[J].Toxicological sciences: an official journal of the Society ofToxicology.2000,55(2):335-42.
[66]郭学鹏,刘玉峰,王家勤.儿童白细胞缺乏症[J].实用儿科临床杂志.1993(03):134-8.
[67] Ziske J, Kunz A, Sewangi J, et al. Hematological changes inwomen and infants exposed to an AZT-containing regimen forprevention of mother-to-child-transmission of HIV in Tanzania[J].PloS one.2013,8(2):e55633.
[68] Bruel H, Chabrolle JP, el Khoury E, et al.[Thrombocytosis andcholestasis in a newborn treated with zidovudine][J]. Archives depediatrie: organe officiel de la Societe francaise de pediatrie.2001,8(8):893-4.
[69] Miguez-Burbano MJ, Burbano X, Rodriguez A, et al.Development of thrombocytosis in HIV+drug users: impact ofantiretroviral therapy[J]. Platelets.2002,13(3):183-5.
[70] Obladen M, Diepold K, Maier RF. Venous and arterialhematologic profiles of very low birth weight infants. EuropeanMulticenter rhEPO Study Group[J]. Pediatrics.2000,106(4):707-11.
[1] Cheng T. Toward 'SMART' stem cells[J]. Gene therapy.2008,15(2):67-73.
[2] Cabrita GJ, Ferreira BS, da Silva CL, et al. Hematopoietic stemcells: from the bone to the bioreactor[J]. Trends in biotechnology.2003,21(5):233-40.
[3] Forsberg EC, Bhattacharya D, Weissman IL. Hematopoietic stemcells: expression profiling and beyond[J]. Stem cell reviews.2006,2(1):23-30.
[4] McNamara LA, Ganesh JA, Collins KL. Latent HIV-1infectionoccurs in multiple subsets of hematopoietic progenitor cells and isreversed by NF-kappaB activation[J]. Journal of virology.2012,86(17):9337-50.
[5] Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al.Perinatal antiretroviral treatment and hematopoiesis inHIV-uninfected infants[J]. AIDS.2003,17(14):2053-61.
[6] Shah MM, Li Y, Christensen RD. Effects of perinatal zidovudineon hematopoiesis: a comparison of effects on progenitors fromhuman fetuses versus mothers[J]. AIDS.1996,10(11):1239-47.
[7] Connor EM, Sperling RS, Gelber R. Reduction of maternal infanttransmission of human immunodeficiency virus type1withzidovudine treatment.Pediatric AIDS Clinical Trials GroupProtocol076Study Group[J]. N Engl Med.1994,331(18):1173-80.
[8]王临虹.艾滋病病毒感染孕产妇治疗及预防艾滋病母婴传播抗病毒药物使用手册[M].北京:人民卫生出版社;2007.1-2.
[9] European Collaborative Study. Levels and patterns of neutrophilcell counts over the first8years of life in children of HIV-1infected mothers[J]. AIDS,2004,18(15):2009-17.
[10]刘景生,张均田.干细胞生物学[M].北京:化学工业出版社;2004.249-60.
[11] Christians U, Gottschalk S, Miljus J, et al. Alterations in glucosemetabolism by cyclosporine in rat brain slices link to oxidativestress: interactions with mTOR inhibitors[J]. British journal ofpharmacology.2004,143(3):388-96.
[12] Lim SE, Copeland WC. Differential incorporation and removal ofantiviral deoxynucleotides by human DNA polymerase gamma[J].The Journal of biological chemistry.2001,276(26):23616-23.
[13] Walker UA, Venhoff N, Koch EC, et al. Uridine abrogatesmitochondrial toxicity related to nucleoside analogue reversetranscriptase inhibitors in HepG2cells[J]. Antiviral therapy.2003,8(5):463-70.
[14] Eriksson S, Xu B, Clayton DA. Efficient incorporation of anti-HIVdeoxynucleotides by recombinant yeast mitochondrial DNApolymerase[J]. The Journal of biological chemistry.1995,270(32):18929-34.
[15] McComsey G, Bai RK, Maa JF, et al. Extensive investigations ofmitochondrial DNA genome in treated HIV-infected subjects:beyond mitochondrial DNA depletion[J]. J Acquir Immune DeficSyndr.2005,39(2):181-8.
[16] Lewis LD, Amin S, Civin CI, et al. Ex vivo zidovudine (AZT)treatment of CD34+bone marrow progenitors causes decreasedsteady state mitochondrial DNA (mtDNA) and increased lactateproduction[J]. Human&experimental toxicology.2004,23(4):173-85.
[17] Gogu SR, Beckman BS, Agrawal KC. Amelioration ofzidovudine-induced fetal toxicity in pregnant mice[J].Antimicrobial agents and chemotherapy.1992,36(11):2370-4.
[18] Gallicchio VS, Hughes NK. Suppression of murine hematopoiesisin vivo after chronic administration of zidovudine: evidence thatzidovudine-induced anemia is the result of decreased bonemarrow-derived, erythropoietin-responsive progenitor cells[J].Proc Soc Exp Biol Med.1992,199(4):459-65.
[19] Gallicchio VS, Hughes NK, Hulette BC. In vitro modulation of thetoxicity associated with the use of zidovudine on normal murine,human, and murine retrovirus-infected hematopoietic progenitorstem cells with basic fibroblast growth factor and synergisticactivity with interleukin-1[J]. Journal of leukocyte biology.1992,51(4):336-42.
[20] Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatalantiretroviral drug exposure on hematologic values inHIV-uninfected children: An analysis of the women and infantstransmission study[J]. The Journal of infectious diseases.2006,194(8):1089-97.
[21] Maida I, Nunez M, Rios MJ, et al. Severe liver disease associatedwith prolonged exposure to antiretroviral drugs[J]. J AcquirImmune Defic Syndr.2006,42(2):177-82.
[22] Floridia M, Tamburrini E, Ravizza M, et al. Antiretroviral therapyat conception in pregnant women with HIV in Italy: wide range ofvariability and frequent exposure to contraindicated drugs[J].Antiviral therapy.2006,11(7):941-6.
[23] Fang JL, Beland FA. Long-term exposure to zidovudine delays cellcycle progression, induces apoptosis, and decreases telomeraseactivity in human hepatocytes[J]. Toxicological sciences: anofficial journal of the Society of Toxicology.2009,111(1):120-30.
[24] Singh A, Hemal A, Agarwal S, et al. A prospective study ofhaematological changes after switching from stavudine tozidovudine-based antiretroviral treatment in HIV-infectedchildren[J]. International journal of STD&AIDS.2014.
[25] Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartumantiretroviral regimens to prevent intrapartum HIV infection[J].The New England journal of medicine.2012,366(25):2368-79.
[1] Forsberg EC, Bhattacharya D, Weissman IL. Hematopoietic stemcells: expression profiling and beyond[J]. Stem cell reviews.2006,2(1):23-30.
[2] Ezoe S, Matsumura I, Satoh Y, et al. Cell cycle regulation inhematopoietic stem/progenitor cells[J]. Cell Cycle.2004,3(3):314-8.
[3] Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versusdifferentiation[J]. Wiley interdisciplinary reviews Systems biologyand medicine.2010,2(6):640-53.
[4] Asnaghi L, Bruno P, Priulla M, et al. mTOR: a protein kinaseswitching between life and death[J]. Pharmacological research: theofficial journal of the Italian Pharmacological Society.2004,50(6):545-9.
[5] Holz MK, Blenis J. Identification of S6kinase1as a novelmammalian target of rapamycin (mTOR)-phosphorylatingkinase[J]. The Journal of biological chemistry.2005,280(28):26089-93.
[6] Adjei AA, Hidalgo M. Intracellular signal transduction pathwayproteins as targets for cancer therapy[J]. Journal of clinicaloncology: official journal of the American Society of ClinicalOncology.2005,23(23):5386-403.
[7] Hay N, Sonenberg N. Upstream and downstream of mTOR[J].Genes&development.2004,18(16):1926-45.
[8] Mansure JJ, Nassim R, Chevalier S, et al. Inhibition of mammaliantarget of rapamycin as a therapeutic strategy in the management ofbladder cancer[J]. Cancer biology&therapy.2009,8(24):2339-47.
[9] Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy ofcancer with rapamycin derivatives[J]. Annals of oncology: officialjournal of the European Society for Medical Oncology/ESMO.2005,16(4):525-37.
[10] Inoki K, Li Y, Zhu T, et al. TSC2is phosphorylated and inhibitedby Akt and suppresses mTOR signalling[J]. Nature cell biology.2002,4(9):648-57.
[11] Xu G, Zhang W, Bertram P, et al. Pharmacogenomic profiling ofthe PI3K/PTEN-AKT-mTOR pathway in common humantumors[J]. International journal of oncology.2004,24(4):893-900.
[12] Wolfram. Update on mTOR Inhibitors in Metastatic Renal Cancer.2007; Available from: http://www.medscape.org/viewarticle/559830.
[13] Heesom KJ, Denton RM. Dissociation of the eukaryotic initiationfactor-4E/4E-BP1complex involves phosphorylation of4E-BP1byan mTOR-associated kinase[J]. FEBS letters.1999,457(3):489-93.
[14] Hoeffer CA, Klann E. mTOR signaling: at the crossroads ofplasticity, memory and disease[J]. Trends in neurosciences.2010,33(2):67-75.
[15] Wendel HG, De Stanchina E, Fridman JS, et al. Survival signallingby Akt and eIF4E in oncogenesis and cancer therapy[J]. Nature.2004,428(6980):332-7.
[16] Myers MP, Stolarov JP, Eng C, et al. P-TEN, the tumor suppressorfrom human chromosome10q23, is a dual-specificityphosphatase[J]. Proceedings of the National Academy of Sciencesof the United States of America.1997,94(17):9052-7.
[17] Tamura M, Gu J, Matsumoto K, et al. Inhibition of cell migration,spreading, and focal adhesions by tumor suppressor PTEN[J].Science.1998,280(5369):1614-7.
[18] Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependencedistinguishes haematopoietic stem cells from leukaemia-initiatingcells[J]. Nature.2006,441(7092):475-82.
[19] Duronio V, Scheid MP, Ettinger S. Downstream signalling eventsregulated by phosphatidylinositol3-kinase activity[J]. Cellularsignalling.1998,10(4):233-9.
[20] Jiang BH, Zheng JZ, Aoki M, et al. Phosphatidylinositol3-kinasesignaling mediates angiogenesis and expression of vascularendothelial growth factor in endothelial cells[J]. Proceedings of theNational Academy of Sciences of the United States of America.2000,97(4):1749-53.
[21] Peponi E, Drakos E, Reyes G, et al. Activation of mammaliantarget of rapamycin signaling promotes cell cycle progression andprotects cells from apoptosis in mantle cell lymphoma[J]. TheAmerican journal of pathology.2006,169(6):2171-80.
[22] Montiel-Duarte C, Cordeu L, Agirre X, et al. Resistance toImatinib Mesylate-induced apoptosis in acute lymphoblasticleukemia is associated with PTEN down-regulation due topromoter hypermethylation[J]. Leukemia research.2008,32(5):709-16.
[23] Yang J, Liu J, Zheng J, et al. A reappraisal by quantitative flowcytometry analysis of PTEN expression in acute leukemia[J].Leukemia.2007,21(9):2072-4.
[24] Chen C, Liu Y, Zheng P. mTOR regulation and therapeuticrejuvenation of aging hematopoietic stem cells[J]. Sciencesignaling.2009,2(98):ra75.
[25] Janzen V, Forkert R, Fleming HE, et al. Stem-cell ageing modifiedby the cyclin-dependent kinase inhibitor p16INK4a[J]. Nature.2006,443(7110):421-6.
[26] van Lohuizen M, Frasch M, Wientjens E, et al. Sequence similaritybetween the mammalian bmi-1proto-oncogene and the Drosophilaregulatory genes Psc and Su(z)2[J]. Nature.1991,353(6342):353-5.
[27] Park IK, Qian D, Kiel M, et al. Bmi-1is required for maintenanceof adult self-renewing haematopoietic stem cells[J]. Nature.2003,423(6937):302-5.
[28] Hanson RD, Hess JL, Yu BD, et al. Mammalian Trithorax andpolycomb-group homologues are antagonistic regulators ofhomeotic development[J]. Proceedings of the National Academy ofSciences of the United States of America.1999,96(25):14372-7.
[29] Park IK, He Y, Lin F, et al. Differential gene expression profiling ofadult murine hematopoietic stem cells[J]. Blood.2002,99(2):488-98.
[30] Lessard J, Sauvageau G. Bmi-1determines the proliferativecapacity of normal and leukaemic stem cells[J]. Nature.2003,423(6937):255-60.
[31] Raaphorst FM. Self-renewal of hematopoietic and leukemic stemcells: a central role for the Polycomb-group gene Bmi-1[J]. Trendsin immunology.2003,24(10):522-4.
[32] Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal ofhematopoietic stem cells mediated by the polycomb gene productBmi-1[J]. Immunity.2004,21(6):843-51.
[33] Molofsky AV, He S, Bydon M, et al. Bmi-1promotes neural stemcell self-renewal and neural development but not mouse growthand survival by repressing the p16Ink4a and p19Arf senescencepathways[J]. Genes&development.2005,19(12):1432-7.
[34] Jacobs JJ, Scheijen B, Voncken JW, et al. Bmi-1collaborates withc-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis viaINK4a/ARF[J]. Genes&development.1999,13(20):2678-90.
[35] Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, andcancer stem cells[J]. Nature.2001,414(6859):105-11.
[36] Oh W, Kim DS, Yang YS, et al. Immunological properties ofumbilical cord blood-derived mesenchymal stromal cells[J].Cellular immunology.2008,251(2):116-23.
[1] Connor EM, Sperling RS, Gelber R. Reduction of maternal infanttransmission of human immunodeficiency virus type1withzidovudine treatment.Pediatric AIDS Clinical Trials GroupProtocol076Study Group[J]. N Engl Med.1994,331(18):1173-80.
[2] WHO, UNAIDS, UNICEF. Towards universal access: scaling uppriority HIV/AIDS interventions in the health sector[J]. WorldHealth Organization. September28,2010
[3] WHO. Antiretroviral drugs for treating pregnant women andpreventing HIV infection in infants.2010; Available from:http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/.
[4]王爱霞,王福祥,毛青, et al.艾滋病诊疗指南.中华医学会第五次全国艾滋病、病毒性丙型肝炎暨全国热带病学术会议.2011:22
[5] Mirochnick M. Antiretroviral pharmacology in pregnant womenand their newborns[J]. Annals of the New York Academy ofSciences.2000,918:287-97.
[6] Public Health Service Task Force.Safety and toxicity of individualantiretroviral agents in pregnancy: supplement toPHSTFrecommendations for use of antiretroviral drugs in intervenpregnant HIV-1infected women for maternal health andinterventions to reduce perinatal HIV-1transmission in theUnitedStates2006[online].[cited2006Oct17]; Available from:http:\\aidsinfo.nih.gov.
[7] Marzolini C, Rudin C, Decosterd LA, et al. Transplacental passageof protease inhibitors at delivery[J]. AIDS.2002,16(6):889-93.
[8] Chappuy H, Treluyer JM, Rey E, et al. Maternal-fetal transfer andamniotic fluid accumulation of protease inhibitors in pregnantwomen who are infected with human immunodeficiency virus[J].Am J Obstet Gynecol.2004,191(2):558-62.
[9] Important change in Sustiva (efavirenz) package insert: change from category C to D,March2005. Bristol-Myers Squibb Company [Internet].2006(Oct24). Available from: http://www.f-da.gov/medwatch/SAFETY/2005/Sustiva_DHCPletter-061005.pdf.
[10] Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartumantiretroviral regimens to prevent intrapartum HIV infection[J].The New England journal of medicine.2012,366(25):2368-79.
[11] Recommendations for Use of Antiretroviral Drugs in PregnantHIV-1-Infected Women for Maternal Health and Interventions toReduce Perinatal HIV Transmission in the United States.Developed by the HHS Panel on Treatment of HIV-InfectedWorking Group of the Office of AIDS Research Advisory Council(OARAC)[Internet].2011. Available from:http://aidsinfo.nih.gov/guidelines.
[12] Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load,zidovudine treatment, and the risk of transmission of humanimmunodeficiency virus type1from mother to infant. PediatricAIDS Clinical Trials Group Protocol076Study Group[J]. The NewEngland journal of medicine.1996,335(22):1621-9.
[13] Cooper ER, Charurat M, Mofenson L, et al. Combinationantiretroviral strategies for the treatment of pregnantHIV-1-infected women and prevention of perinatal HIV-1transmission[J]. J Acquir Immune Defic Syndr.2002,29(5):484-94.
[14]王临虹,方利文,王前, et al.我国艾滋病母婴传播水平传播时期及干预效果研究[J].中国艾滋病性病.2008(05):435-8.
[15]王临虹.艾滋病病毒感染孕产妇治疗及预防艾滋病母婴传播抗病毒药物使用手册[M].北京:人民卫生出版社;2007.1-2.
[16] McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-courseAZT plus3TC to reduce nevirapine resistance in the prevention ofmother-to-child HIV transmission: a randomized clinical trial[J].PLoS Med.2009,6(10):e1000172.
[17] Meda N, Leroy V, Viho I, et al. Field acceptability andeffectiveness of the routine utilization of zidovudine to reducemother-to-child transmission of HIV-1in West Africa[J]. AIDS.2002,16(17):2323-8.
[18]中国疾病预防控制中心性病艾滋病预防控制中心.卫生计生委:1至9月新发现艾滋病病毒感染者约7万例2013[cited201312-01]; Available from: http://www.chinaids.org.cn/jkjy/sjazbr1/rdgz1/201312/t20131201_90833.htm.
[19]中国疾病预防控制中心性病艾滋病预防控制中心.2011年中国艾滋病疫情估计[J].中国艾滋病性病.2012(01):1-5.
[20]中华人民共和国国家卫生和计划生育委员会.我国艾滋病防控工作背景2013[cited201311-30]; Available from:http://www.nhfpc.gov.cn/jkj/s3586/201312/2b871ccd2ef446eb9542875d3d68bbca.shtml.
[21] Antiretroviral Pregnancy Registry Steering Committee.Antiretroviral Pregnancy Registry International interim report for1January1989-31July2010[J]. Antiviral Pregnancy Registry.2010July
[22] Saitoh A, Hull AD, Franklin P, et al. Myelomeningocele in aninfant with intrauterine exposure to efavirenz[J]. Journal ofperinatology: official journal of the California PerinatalAssociation.2005,25(8):555-6.
[23] Watts DH. Teratogenicity risk of antiretroviral therapy inpregnancy[J]. Curr HIV/AIDS Rep.2007,4(3):135-40.
[24] Ford N, Calmy A, Mofenson L. Safety of efavirenz in the firsttrimester of pregnancy: an updated systematic review andmeta-analysis[J]. AIDS.2011,25(18):2301-4.
[25] Brogly SB, Abzug MJ, Watts DH, et al. Birth defects amongchildren born to human immunodeficiency virus-infected women:pediatric AIDS clinical trials protocols219and219C[J]. ThePediatric infectious disease journal.2010,29(8):721-7.
[26] Townsend Cl, Cortina BM, Peckham CS, et al. Low rates ofmotherto-child transmission of HIV following effective pregnancyinterventions in the United Kingdom and Ireland,2000-2006[J].AIDS.2008,22(8):973-81.
[27] Townsend CL, Willey BA, Cortina-Borja M, et al. Antiretroviraltherapy and congenital abnormalities in infants born toHIV-infected women in the UK and Ireland,1990-2007[J]. AIDS.2009,23(4):519-24.
[28] Townsend CL, Tookey PA, Cortina-Borja M, et al. Antiretroviraltherapy and congenital abnormalities in infants born toHIV-1-infected women in the United Kingdom and Ireland,1990to2003[J]. J Acquir Immune Defic Syndr.2006,42(1):91-4.
[29] European Collaborative Study. Does highly active antiretroviraltherapy increase the risk of congenital abnormalities in HIVinfected women?[J]. Acquir Immune Defic Syndr.2005,40(1):116-8.
[30] Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infantoutcomes among HIV-infected women taking long-term ART withand without tenofovir in the DART trial[J]. PLoS Med.2012,9(5):e1001217.
[31] Tariq S, Thorne C, Townsend C. Pregnancy outcomes in HIVinfected women using non-zidovudine HAART in Europe:2000to2009[895].17th Conference on Retroviruses and OpportunisticInfections; San Francisco2010.
[32] Jungmann EM, Mercey D, DeRuiter A, et al. Is first trimesterexposure to the combination of antiretroviral therapy and folateantagonists a risk factor for congenital abnormalities?[J]. Sexuallytransmitted infections.2001,77(6):441-3.
[33] Forna F, McConnell M, Kitabire FN, et al. Systematic review ofthe safety of trimethoprim-sulfamethoxazole for prophylaxis inHIV-infected pregnant women: implications for resource-limitedsettings[J]. AIDS reviews.2006,8(1):24-36.
[34] European Collaborative Study. Exposure to antiretroviral therapy inutero or early life: the health of uninfected children born toHIV-infected women[J]. Acquir Immune Defic Syndr.2003,32(4):380-7.
[35] Taha TE KN, Gibbons A, et al. Effect of HIV-1antiretroviralprophylaxis on hepatic and hematological parameters of Africaninfants[J]. AIDS.2002,16(6):851-8.
[36] Shapiro RL, Ndung'u T, Lockman S, et al. Highly activeantiretroviral therapy started during pregnancy or postpartumsuppresses HIV-1RNA, but not DNA, in breast milk[J]. TheJournal of infectious diseases.2005,192(5):713-9.
[37] Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, et al.Perinatal antiretroviral treatment and hematopoiesis inHIV-uninfected infants[J]. AIDS.2003,17(14):2053-61.
[38] Nielsen-Saines K, Watts D H, VG V. Three postpartumantiretroviralregimens to prevent intrapartum HIV infection[J]. TheNew England journal of medicine.2012,366(25):2368-79.
[39] The Perinatal Safety Review Working G. Nucleoside exposure inthe children of HIV-infected women receiving antiretroviral drugs:absence of clear evidence for mitochondrial disease in childrenwho died before5years of age in fiv United States cohorts[J]. JAcquir Immune Defi Syndr.2000,25(3):261-8.
[40] European Collaborative Study. Levels and patterns of neutrophilcell counts over the first8years of life in children of HIV-1infected mothers[J]. AIDS.2004,18(15):2009-17.
[41] Bunders MJ, Bekker V, Scherpbier HJ, et al. Haematologicalparameters of HIV-1-uninfected infants born to HIV-1-infectedmothers[J]. Acta Paediatr.2005,94(11):1571-7.
[42] Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatalantiretroviral drug exposure on hematologic values inHIV-uninfected children: An analysis of the women and infantstransmission study[J]. The Journal of infectious diseases.2006,194(8):1089-97.
[43] Feiterna-Sperling C, Weizsaecker K, Buhrer C, et al. Hematologiceffects of maternal antiretroviral therapy and transmissionprophylaxis in HIV-1-exposed uninfected newborn infants[J]. JAcquir Immune Defic Syndr.2007,45(1):43-51.
[44] Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infantantiretroviral drugs to reduce HIV-1transmission[J]. The NewEngland journal of medicine.2010,362(24):2271-81.
[45] The Kesho Bora Study Group. Triple antiretroviral compared withzidovudine and single-dose nevirapine prophylaxis duringpregnancy and breastfeeding for prevention of mother-to-childtransmission of HIV-1(Kesho Bora study): a randomisedcontrolled trial[J]. The Lancet infectious diseases.2011,11(3):171-80.
[46] Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens inpregnancy and breast-feeding in Botswana[J]. The New Englandjournal of medicine.2010,362(24):2282-94.
[47] Dryden-Peterson S, Shapiro RL, Hughes MD, et al. Increased riskof severe infant anemia after exposure to maternal HAART,Botswana[J]. J Acquir Immune Defic Syndr.2011,56(5):428-36.
[48] Bae WH, Wester C, Smeaton LM, et al. Hematologic and hepatictoxicities associated with antenatal and postnatal exposure tomaternal highly active antiretroviral therapy among infants[J].AIDS.2008,22(13):1633-40.
[49] Toltzis P, Marx CM, Kleinman N, et al. Zidovudine-associatedembryonic toxicity in mice[J]. The Journal of infectious diseases.1991,163(6):1212-8.
[50] Olivero OA, Fernandez JJ, Antiochos BB, et al. Transplacentalgenotoxicity of combined antiretroviral nucleoside analoguetherapy in Erythrocebus patas monkeys[J]. J Acquir Immune DeficSyndr.2002,29(4):323-9.
[51] Brogly S, Williams P. In utero nucleoside reverse transcriptaseinhibitor exposure and cancer in HIV-uninfected children: anupdate from the pediatric AIDS clinical trials group219and219Ccohorts[J]. J Acquir Immune Defic Syndr.2006,41(4):535-6.
[52] Oleske JM. Long-term outcomes in infants born to HIV-infectedwomen[J]. J Acquir Immune Defic Syndr.2003,32(4):353.
[53] Poirier MC, Olivero OA, Walker DM, et al. Perinatal genotoxicityand carcinogenicity of anti-retroviral nucleoside analog drugs[J].Toxicology and applied pharmacology.2004,199(2):151-61.
[54] Combination antiretroviral therapy and duration of pregnancy[J].AIDS.2000,14(18):2913-20.
[55] Thorne C, Patel D, Newell ML. Increased risk of adversepregnancy outcomes in HIV-infected women treated with highlyactive antiretroviral therapy in Europe[J]. AIDS.2004,18(17):2337-9.
[56] Townsend CL, Cortina-Borja M, Peckham CS, et al. Antiretroviraltherapy and premature delivery in diagnosed HIV-infected womenin the United Kingdom and Ireland[J]. AIDS.2007,21(8):1019-26.
[57] Chiesa E, Repetto D, Melzi S. Increasing risk of preterm deliverywith more potent antiretroviral therapy (ART)Increasing risk ofpreterm delivery with more potent antiretroviral therapy (ART).
[M]: The Gardiner-Caldwell Group Ltd,Tytherington, Cheshire,UK;2007.
[58] Boer K, Nellen JF, Patel D, et al. The AmRo study: pregnancyoutcome in HIV-1-infected women under effective highly activeantiretroviral therapy and a policy of vaginal delivery[J]. BJOG:an international journal of obstetrics and gynaecology.2007,114(2):148-55.
[59] Grosch-Woerner I, Puch K, Maier RF, et al. Increased rate ofprematurity associated with antenatal antiretroviral therapy in aGerman/Austrian cohort of HIV-1-infected women[J]. HIVmedicine.2008,9(1):6-13.
[60] Watts DH, Mofenson LM. Antiretrovirals in pregnancy: a note ofcaution[J]. The Journal of infectious diseases.2012,206(11):1639-41.
[61] Ndirangu J, Newell ML, Bland RM, et al. Maternal HIV infectionassociated with small-for-gestational age infants but not pretermbirths: evidence from rural South Africa[J]. Hum Reprod.2012,27(6):1846-56.
[62] Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviraltherapy and adverse birth outcomes among HIV-infected women inBotswana[J]. The Journal of infectious diseases.2012,206(11):1695-705.
[63] Darak S, Darak T, Kulkarni S, et al. Effect of highly activeantiretroviral treatment (HAART) during pregnancy on pregnancyoutcomes: experiences from a PMTCT program in western India[J].AIDS patient care and STDs.2013,27(3):163-70.
[64] Bera E MR. Safety of nevirapine in HIV-infected pregnant womeninitiating antiretroviral therapy at higher CD4counts: a systematicreview and meta analysis[J]. South Afr Med J.2012,102(11pt1):855-9.
[65] Jones CE, Naidoo S, De Beer C, et al. Maternal HIV infection andantibody responses against vaccine-preventable diseases inuninfected infants[J]. JAMA: the journal of the American MedicalAssociation.2011,305(6):576-84.
[66] Miles DJ, Gadama L, Gumbi A, et al. Human immunodeficiencyvirus (HIV) infection during pregnancy induces CD4T-celldifferentiation and modulates responses to Bacille Calmette-Guerin(BCG) vaccine in HIV-uninfected infants[J]. Immunology.2010,129(3):446-54.
[67] Slogrove AL, Cotton MF, Esser MM. Severe infections inHIV-exposed uninfected infants: clinical evidence ofimmunodeficiency[J]. Journal of tropical pediatrics.2010,56(2):75-81.
[68] Gompels UA, Larke N, Sanz-Ramos M, et al. Humancytomegalovirus infant infection adversely affects growth anddevelopment in maternally HIV-exposed and unexposed infants inZambia[J]. Clinical infectious diseases: an official publication ofthe Infectious Diseases Society of America.2012,54(3):434-42.
[69] Karpelowsky JS, Millar AJ, van der Graaf N, et al. Comparison ofin-hospital morbidity and mortality in HIV-infected and uninfectedchildren after surgery[J]. Pediatric surgery international.2012,28(10):1007-14.
[70] Karpelowsky JS, Leva E, Kelley B, et al. Outcomes of humanimmunodeficiency virus-infected and-exposed childrenundergoing surgery--a prospective study[J]. Journal of pediatricsurgery.2009,44(4):681-7.
[71] Karpelowsky JS, Millar AJ, van der Graaf N, et al. Outcome ofHIV-exposed uninfected children undergoing surgery[J]. BMCpediatrics.2011,11:69.
[72] Hankin C, Thorne C, Newell ML. Does exposure to antiretroviraltherapy affect growth in the first18months of life in uninfectedchildren born to HIV-infected women?[J]. J Acquir Immune DeficSyndr.2005,40(3):364-70.
[73] Powis KM, Smeaton L, Ogwu A, et al. Effects of in uteroantiretroviral exposure on longitudinal growth of HIV-exposeduninfected infants in Botswana[J]. J Acquir Immune Defic Syndr.2011,56(2):131-8.
[74] Williams PL, Marino M, Malee K, et al. Neurodevelopment and inutero antiretroviral exposure of HIV-exposed uninfected infants[J].Pediatrics.2010,125(2):e250-60.
[75] Lattner J, Soclas ME, Buraschi M F. Growth andneurodevelopment in HIV-uninfected children born fromHIV-infected women in a public general hospital from Argentina
[WEPE0145]. Paper presented at: XVIII International AIDSConference. Vienna2010.
[76] Wimalasundera RC, Larbalestier N, Smith JH, et al. Pre-eclampsia,antiretroviral therapy, and immune reconstitution[J]. Lancet.2002,360(9340):1152-4.
[77] Suy A, Martinez E, Coll O, et al. Increased risk of pre-eclampsiaand fetal death in HIV-infected pregnant women receiving highlyactive antiretroviral therapy[J]. AIDS.2006,20(1):59-66.
[78] Flint OP, Noor MA, Hruz PW, et al. The role of protease inhibitorsin the pathogenesis of HIV-associated lipodystrophy: cellularmechanisms and clinical implications[J]. Toxicologic pathology.2009,37(1):65-77.
[79] Grinspoon S, Carr A. Cardiovascular risk and body-fatabnormalities in HIV-infected adults[J]. The New England journalof medicine.2005,352(1):48-62.
[80] Jones R, Sawleshwarkar S, Michailidis C, et al. Impact ofantiretroviral choice on hypercholesterolaemia events: the role ofthe nucleoside reverse transcriptase inhibitor backbone[J]. HIVmedicine.2005,6(6):396-402.
[81] Stanley TL, Grinspoon SK. Body composition and metabolicchanges in HIV-infected patients[J]. The Journal of infectiousdiseases.2012,205Suppl3:S383-90.
[82] Dimock D, Thomas V, Cushing A, et al. Longitudinal assessmentof metabolic abnormalities in adolescents and young adults withHIV-infection acquired perinatally or in early childhood[J].Metabolism: clinical and experimental.2011,60(6):874-80.
[83] Hazra R, Cohen RA, Gonin R. Lipid levels in the second year oflife among HIV-infected and HIV-exposed uninfected LatinAmerican children[J]. AIDS.2012,26(2):235-40.
[84] Woollett LA. Maternal cholesterol in fetal development: transportof cholesterol from the maternal to the fetal circulation[J]. TheAmerican journal of clinical nutrition.2005,82(6):1155-61.
[85] Senise JF, Castelo A, Martinez M. Current treatment strategies,complications and considerations for the use of HIV antiretroviraltherapy during pregnancy[J]. AIDS reviews.2011,13(4):198-213.
[86] Mudd LM HC, Catov JM,Senagore PK, Evans RW. Maternal lipidsat mid-pregnancy and the risk of preterm delivery[J]. Acta ObstetGynecol Scand.2012,91(6):726-35.
[87] Tien PC, Schneider MF, Cox C, et al. Association of HIV infectionwith incident diabetes mellitus: impact of using hemoglobin A1Cas a criterion for diabetes[J]. J Acquir Immune Defic Syndr.2012,61(3):334-40.
[88] Geffner ME, Patel K, Miller TL, et al. Factors associated withinsulin resistance among children and adolescents perinatallyinfected with HIV-1in the pediatric HIV/AIDS cohort study[J].Horm Res Paediatr.2011,76(6):386-91.
[89] Gutierrez AD, Balasubramanyam A. Dysregulation of glucosemetabolism in HIV patients: epidemiology, mechanisms, andmanagement[J]. Endocrine.2012,41(1):1-10.
[90] Watts DH, Balasubramanian R, Maupin RT. Maternal toxicity andpregnancy complications in HIV-infected women receivingantiretroviral therapy: an analysis of the PACTG316Study[J]. AmJ Obstet Gynecol.2004,190(2):506-16.
[91] Teissier R, Nowak E, Assoun M, et al. Maternal phenylketonuria:low phenylalaninemia might increase the risk of intra uterinegrowth retardation[J]. J Inherit Metab Dis.2012,35(6):993-9.
[92] Apostolova N, Blas-Garcia A, Esplugues JV. Mitochondrialinterference by anti-HIV drugs: mechanisms beyond Pol-gammainhibition[J]. Trends in pharmacological sciences.2011,32(12):715-25.
[93] Chan SS, Santos JH, Meyer JN, et al. Mitochondrial toxicity inhearts of CD-1mice following perinatal exposure to AZT,3TC, orAZT/3TC in combination[J]. Environ Mol Mutagen.2007,48(3-4):190-200.
[94] Divi Rl, Leonard SL, Kuo MM, et al. Transplacentally exposedhuman and monkey newborn infants show similar evidence ofnucleoside reverse transcriptase inhibitor-induced mitochondrialtoxicity[J]. Environ Mol Mutagen.2007Apr-May,48(3-4):201-9.
[95] Heidari S, Mofenson L, Cotton MF, et al. Antiretroviral drugs forpreventing mother-to-child transmission of HIV: a review ofpotential effects on HIV-exposed but uninfected children[J]. JAcquir Immune Defic Syndr.2011,57(4):290-6.
[96] Miller TI, Borkowsky W, DiMeglio LA, et al. Metabolicabnormalities and viral replication are associated with biomarkersof vascular dysfunction in HIV-infected children[J]. HIV medicine.2012,13(5):264-75.
[97] Ross AC, Leong T, Avery A, et al. Effects of in utero antiretroviralexposure on mitochondrial DNA levels, mitochondrial function andoxidative stress[J]. HIV medicine.2012,13(2):98-106.
[98] Hernandez S, Moren C, Lopez M, et al. Perinatal outcomes,mitochondrial toxicity and apoptosis in HIV-treated pregnantwomen and in-utero-exposed newborn[J]. AIDS.2012,26(4):419-28.
[99] Brogly SB, Foca M, Deville JG, et al. Potential confounding of theassociation between exposure to nucleoside analogues andmitochondrial dysfunction in HIV-uninfected and indeterminateinfants[J]. J Acquir Immune Defic Syndr.2010,53(1):154-7.
[100] Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrialdysfunction in HIV-1-exposed but uninfected infants: clinicalscreening in a large prospective cohort[J]. AIDS.2003,17(12):1769-85.
[101] Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleosidereverse transcriptase inhibitor exposure and signs of possiblemitochondrial dysfunction in HIV-uninfected children[J]. AIDS.2007,21(8):929-38.
[102] Aldrovandi GM, Chu C, Shearer WT, et al. Antiretroviral exposureand lymphocyte mtDNA content among uninfected infants ofHIV-1-infected women[J]. Pediatrics.2009,124(6):e1189-97.
[103] Cote HC, Raboud J, Bitnun A, et al. Perinatal exposure toantiretroviral therapy is associated with increased bloodmitochondrial DNA levels and decreased mitochondrial geneexpression in infants[J]. The Journal of infectious diseases.2008,198(6):851-9.
[104] Noguera A, Fortuny C, Munoz-Almagro C, et al. Hyperlactatemiain human immunodeficiency virus-uninfected infants who areexposed to antiretrovirals[J]. Pediatrics.2004,114(5):e598-603.
[105] Alimenti A, Burdge DR, Ogilvie GS, et al. Lactic acidemia inhuman immunodeficiency virus-uninfected infants exposed toperinatal antiretroviral therapy[J]. The Pediatric infectious diseasejournal.2003,22(9):782-9.
[106] Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels inchildren perinatally treated with antiretroviral agents to preventHIV transmission[J]. AIDS.2001,15(8):1074-5.
[107] Ekouevi DK, Toure R, Becquet R, et al. Serum lactate levels ininfants exposed peripartum to antiretroviral agents to preventmother-to-child transmission of HIV: Agence Nationale deRecherches Sur le SIDA et les Hepatites Virales1209study,Abidjan, Ivory Coast[J]. Pediatrics.2006,118(4):e1071-7.
[108] Blanche S. Possible long-term effect of in utero antiretroviralexposure?[J]. Archives de pediatrie: organe officiel de la Societefrancaise de pediatrie.2007,14(6):610-1.
[109] Foster C, Lyall H. HIV and mitochondrial toxicity in children[J].The Journal of antimicrobial chemotherapy.2008,61(1):8-12.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |